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ABSTRACT
An investigation of the metabolism of fructose by rat 
liver has been carried out with particular reference to control 
by sex hormones and the possible relationship in humans between 
dietary sucrose, blood triglycerides and heart disease.
The incorporation of label from ^^Ofructose and ^^C- 
glucose into liver triglycerides has been studied* the former 
sugar was observed to produce the greater incorporation.
Fructokinase activity in liver tissues from male and 
female animals at various stages of development has been 
measured and sex and age differences were noted. Testosterone 
injections elevated the level of fructokinase activity in male 
and female rats and produced similar effects with liver slices. 
Estrone, however, lowered the activity of the enzyme in male 
animals and increased it in females. The mode of action of 
testosterone has been investigated.
Fructose phosphate aldolase activity is higher in liver
from male rats than from females and this may be related to the
14relatively rapid transfer of label from C-fructose to trioses 
when the ketose is incubated with male liver extracts. 
Testosterone injections produce no change in the levels of the 
aldolase.
Some related, preliminary work on the purification of 
liver fructokinase suid the analysis of glyceride fatty acids 
from various rat tissues is also described.
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I N T R O D U C T I O N
Atherosclerosis; the disease process
The commonest cause of coronary heart disease is coronary 
atherosclerosis. Atherosclerosis tends to Increase progressively 
with age but sometimes occurs with moderate or intense severity 
even in young adults. However, coronary heart disease, the clinical 
entity, may be absent even with moderately severe coronary lesions 
if the blood flow is not significantly diminished. It is, therefore, 
important to distinguish between coronary atherosclerosis, a pathologic 
term, and coronary heart disease due to atherosclerosis, the clinical 
terra (1).
The word arteriosclerosis (2) is a generic terra associated with 
thickening and hardening of arteries. If this occurs and (a), there 
is an absence of scarring of the intimai coat produced by infections 
such as syphilis or tuberculosis); (b), no inflammation of the coronary 
artery; and (c), no thrombboangitis (inflammation of the intima of a 
vessel, with thrombosis) or polyarteritis, then the condition is kno%m 
as atherosclerosis (3). This is the association of a sclerosising 
process with the accumulation of fatty material.
To facilitate the standardization of pathological criteria and 
terminology in respect of artherosclerosis the W.H.O. proposed (W.H.O.
Tech.Rep.No. 143, 1958) the following definition; "Atherosclerosis is 
a variable combination of changes of the intima of arteries (as 
distinguished from arterioles) consisting of a focal accumulation of 
lipids, complex carbohydrates, blood and blood products, fibrous tissue 
and calcium deposits, and associated with medial changes".
The diagnosis of coronary heart disease is based on evidence of 
an old myocardial infaction, or of angina pectoris in a patient with 
no evidence of syphilis or valvular heart disease. Coronary athero­
sclerosis is the disease most frequently associated with angina pectoris.
At least one major coronary vessel shows either extreme narrowing or complete 
obstruction. Angina pectoris is much more common in males than in 
females and increases in frequency with age, especially above the age 
of fifty. Diabetes mellitus, hypertension, hypercholesterolemia and
familiallipemia predispose to angina pectoris probably because of 
their relation to coronary atherosclerosis*
The cardiac pain of angina pectoris is similar to that of 
myocardial infarction in which it is known that blood flow has been 
interrupted by a coronary thrombosis. The essential difference is 
the greater severity and more prolonged duration of pain in myo­
cardial infarction, which is explained by the suddenness, complete­
ness and irreversibility of obstruction of a major coronary artery (1).
Myocardial infarction should not be regarded as identical with 
coronary thrombosis or occlusion. The commonest cause of the onset 
of angina pectoris is probably a coronary occlusion, but one that, 
because of the adequacy of collateral circulation, does not result 
in a prompt myocardial infarction. However, since in most cases of 
angina pectoris the underlying disease is severe coronary athero­
sclerosis ojf aortic valvular disease, heart failure frequently 
occurs as an eventual result of myocardial damage.
Acute myocardial infarction is a clinical syndrome resulting 
from sudden and persistent curtailment of the myocardial blood 
supply. Thrombosis, secondary to atherosclerosis, is the cause in 
more than 75 per cent of the cases of myocardial infarction. A fissure 
in an atherosclerotic plaque with intimai hemorrhage is often the 
initial factor in the occlusion. The thrombus occurs usually over 
a short distance (5mm or less) and involves a major coronary artery 
in its proximal position. The occurrence and extent of infarction 
depends in large measure on the distribution of blood supply from the 
various coronary arteries and on the site of thrombosis. The latter 
determines the collateral circulation available from branches of the 
occluded artery proximal to the occlusion and from neighbouring 
coronary arteries. Thus, it is possible for collateral vessels to 
maintain viability and prevent infarction, despite a coronary 
thrombosis. The coronary occlusion may result in infarction or only 
in potential myocardial ischemia (angina pectoris), or may cause no 
clinical symptoms. If infarction occurs, it may extend through the 
entire thickness of the ventricular wall (transmural infarction), or 
it may cause more limited necrosis, which is usually situated pre­
dominantly in the subendocardium. The subendocardial area is more
likely to suffer from a lack of blood supply than the subepicardial.
There is little theoretical or experimental evidence that 
arterial thrombosis can be prevented by the use of anti-coagulants. 
Clinical studies suffer from the relative paucity of cases or un­
satisfactory controls, the latter due to problems in matching patients 
to be treated and those who serve as controls. However, despite the 
absence of scientific proof of their value, the use of anti-coagulants 
in acute myocardial infarction appears to be justified,because the 
vast majority of studies in every part of the world have consistently 
disclosed a significant reduction in mortality and an impressive 
diminution in the frequency of thromboembolism in patients treated 
with anti-coagulants.
Whereas anti-coagulants are given with the aim of preventing 
thromboembolic complications or extension or recurrence of coronary 
thrombosis, fibrinolytic agents are designed to induce lysis of the 
clot already present. In animals, fibrinolytic agents have been 
observed to hasten lysis of induced coronary thrombi, to reduce the 
size of infarct and to promote healing by diminishing capillary con­
gestion and edema and eliminating microthrombi.
Arterial Hypertension (4) in general, rises with age in urban 
communities. The rise in diastolic (expansion of heart vessels) and 
systolic (contraction of heart musculature) pressures is greater in 
females at the menopause than at the corresponding age in males.
The features it shares with all other hypertensive manifestations are 
those due to the increased load put upon the heart and the blood 
vessels in different territories. A main finding is the increased 
incidence of atheroma, both experimentally and pathologically. The 
increased pressure leads to hypertrophy of the left ventricle and a 
tendency to angina pectoris and myocardial infarction.
The combination of hyperinsulin response, insulin resistance 
and impaired glucose tolerance is now being frequently recognized in 
patients with atherosclerosis. Also in those with increased concen­
trations of the serum lipids, particularly triglycerides, commonly 
associated with atherosclerosis (5). The sex hormones affect both the 
amount and the distribution of fat. Women, for example, have a greater 
amount of subcutaneous fat than men. The relationship between parity
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and obesity and the frequent menopausal gain in weight , although 
difficult to document, suggests a possible role of female sex 
hormones in the regulation of fat metabolism. The obesity of 
eunuchs suggests further that absence of male sex hormones also 
promotes adiposity. The hypogonad obesity that occurs in children 
just prior to adolescence disappears with puberty, at which time 
the adult distribution of fat takes place (5).
Atherosclerosis is more common in acquired than in inherited 
obesity and in the male type than in the female type. The incidence 
of atherosclerosis is much lower in pre-menopausal females, but 10 
years after the menopause approaches that of males. Ko single agent 
has been pinpointed as the causal agent of the atherosclerotic plaque. 
The lesions consist of subendothelial accumulation of cholesterol, 
triglyceride and phospholipids that partially and at times completely 
occlude the lumen of the artery. Biochemical studies have demonstrated 
that cholesterol and triglyceride constituents are mainly derived from 
plasma lipids, whereas the phospholipids are at least partially 
synthesised in the vessel wall. The association between atherosclerosis 
and increased concentration of p lipoproteins and very low density 
lipoproteins, suggests that such triglyceride-rich macromolecules 
are particularly likely to become ensnared in the vessel wall.
A certain amount of lipid exchange between intima and plasma is 
normal, and such lipid is metabolized by the vessel wall. However, 
either because the entry of lipid becomes too great or because the 
metabolic processes by which it is normally removed are impaired, 
lipid accumulation becomes excessive and plaque formation ensues. The 
lipid is at first present in foam cells. The early lesions consist 
chiefly of triglyceride and, according to some workers, cholesterol is 
not a prominent constituent of the early plaque. With time the tri­
glycerides and phospholipids are metabolized leaving behind cellular 
debris and the non-metabolizable cholesterol as the chief constituents 
of the older plaque, BÎJttchcr et al (6) reported that a high per­
centage of triglycerides from the coronary arteries, as opposed to the 
aorta, predominated over all the other lipid fractions in the early 
stages of atherosclerosis. This percentage of triglycerides was higher 
than the sterol esters in the latter stages of the disease, in spite of
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the higher percentage of the latter in the more severely diseased 
arteries. The percentage of phospholipids and of free fatty acids 
were not significantly different at the two stages. Eventually 
fibrous tissue and calcium replace the lipids.
The localization of atherosclerotic plaques at sites of 
injury and at points of bifurcation of arteries,and the greater 
incidence of atherosclerosis in hypertensive persons demonstrate 
that local injury and pressure relationships are important factors 
in plaque formation.
An alternative theory attributes plaque formation to intra- 
vascular coagulation initiated by increased platelet stickiness and 
platelet agglomeration or by a shift in the balance between fibrin 
formation, with secondary enmeshment of circulating lipids (7).
Three important biochemical findings have been identified in 
patients with coronary artery disease : (i), elevation of serum 
cholesterol concentration, (ii), increase in serum triglycerides 
and associated very low density lipoproteins, and (iii), impaired 
carbohydrate tolerance.
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Myocordial Infarction
From a pathological point of view, the clinical opinion that 
angina pectoris is a manifestation of myocardial ischemia, usually 
from coronary atherosclerosis, is so strongly supported as to be 
axiomatic (8).
Platelet thromboemboli may be important not only in the 
development of some forms of atherosclerosis and occlusive thrombi, 
but also in initiating disturbances of the microcirculation (9).
Epidemiological studies of myocardial infarction, genetic and 
environmental factors, show that each of these variables can be 
modified and that coronary disease and myocardial infarction does not 
run an invariant course (10).
Epidemiological studies, and observations on animals, stimulated 
by these studies have indicated several factors involved:
(a) Ethnic differences. Persons with cholesterol and lipid levels 
greatly below those seen in the more affluent countries in the world 
have a reduced incidence of atherosclerotic disease in general; this 
is reflected in a reduced amount of coronary atherosclerosis and 
myocardial infarction (11-13). Ethnic differences in coronary heart 
disease among males in U.S.A. revealed a higher incidence for whites 
than for blacks (14-17). In contrast differences by social class 
found in the prevalence survey among white males were not found in the 
incidence study (14). Further, no differences were found by ethnic 
group for females; however within ethnic groups white males had a rate 
five times higher than white females, while the ratio for black males 
to females was only 2 to 1 (14). Yudkin (18) found a mortality rate 
two to three times greater in males than in females in Britain,
(b) Diet. The proportion of calories derived from saturated and 
unsaturated fat and the number of calories consumed per day have an 
effect on the lipid content of the plasma in man (19). Experiments 
have been carried out to elevate serum cholesterol in pigs by the 
addition of dietary lard or tallow (but not vegetable oil) to the diet 
(20-22). Serum cholesterol tended to increase with increasing degree 
of saturation of the fats tested. Similar trends have been reported 
with rats (23), chickens (24) and with humans (25).
Hutagalung (26) reports that the addition of 5% lard, beef tallow
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or sheep tallow to a 12% protein diet resulted in increased cholesterol 
in serum, l.dorsi muscle and liver tissue and increased total lipid in 
the serum, whereas the addition of 5% corn oil elevated only serum 
total lipid. No significant differences in cholesterol levels were 
observed amongst pigs given these dietary treatments. The addition of 
12.5% lard to diets containing 13 or 19% protein,elevated serum, muscle 
and liver cholesterol and serum total lipid, and depressed cholesterol 
in the backfat. Increasing the dietary protein level from 13% to 19% 
tended to reduce cholesterol in serum and muscle tissue, and markedly 
depressed total lipid in the serum and cholesterol in liver tissue.
The addition of 1% cholesterol to the diet resulted in a trend toward 
increased total lipid in serum, and cholesterol in muscle and backfat 
and markedly elevated cholesterol in serum and liver tissue. Addition 
of a combination of 1% cholesterol and 12.5% lard to a 13% protein 
diet resulted in increases in serum cholesterol values significantly 
greater than the additive effects resulting from single additions of 
dietary cholesterol and lard. Yudkin (18) found no relationship 
between coronary mortality and consumption of vegetable fat or animal 
fats, nor was the consumption of hardened fats related to coronary 
mortality. In his survey of the years 1928-54 consumption of hardened 
fats increased considerably while coronary mortality fell.
(i) Dietary alternations of the Lipoprotein Levels
Ockner (27) observed the effect of various intraduodenally 
infused long chain fatty acids on the very low density lipoproteins 
(U.L.D.L.) in intestinal lymph of rats. He found that, compared with 
controls, all fatty acids (palmitic, oleic, linoleic) resulted in 
significant increases in chylomicron (S^ >  400) triglyceride. In 
addition palmitic acid resulted in a twofold increase in VLDL ($£20-400) 
triglyceride, whereas with the absorption of oleic or linoleic acid 
VLDL triglyceride did not change significantly. Although the absolute 
amount of endogenous cholesterol in intestinal lymph was not significantly 
affected by lipid absorption under these conditions, its lipoprotein 
distribution differed substantially among the lipid infysed groups.
The studies demonstrated that dietary long chain fatty acids differ 
significantly in their effects upon the transport of triglyceride and 
cholesterol by lipoproteins.
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These findings together with the observed differences in rates 
of removal of chylomicrons and VLDL from plasma (the half time of plasma 
survival of VLDL cholesterol-^was twice that of chylAmicron 
cholesterol-^^C), suggest that variations in lipoprotein production at 
the intestinal level may be reflected in differences in the subsequent 
metabolism of absorbed dietary and endogenous lipids. Gofman (23) 
found that the p-lipoproteins were raised in four out of five subjects 
when the carbohydrate in the diet was raised, the nature of the carbo­
hydrates not being stated. Gofman put forward the view that the 20- 
400-p-lipoproteins are controlled by the level of dietary carbohydrate.
Studies on the effect of variation in the fibre content of the
diet on the serum triglycerides and total cholesterol concentration of
a community of Cistercian monks, showed no change in the serum-cholesterol 
with an enhanced cereal-fibre content. In the control group, where 
dietary fibre came entirely from non-cereal vegetables, the serum- 
cholesterol fell, but began to increase after eight weeks. Increasing 
the fibre content of the diet reduces the serum triglyceride concen­
tration (P<0.05) in men under the age of 40, The values do not differ 
statistically for the men over 40 (29).
Stead (30) claims that the amount of sucrose in the diet has
measurable but not marked effects on the cholesterol and total lipid 
content of the plasma. However, Ahrens et al (31) advanced the hypothesis 
that hyperlipemia could be carbohydrate-induced. This was confirmed in 
diabetics when the isocaloric substitution of carbohydrate for fat in 
the diet resulted in an increase in the serum lipid level (32). Corn 
starch as the main carbohydrate in a low fat diet of healthy men lowered 
the total lipid concentration over a period of 25 days,whereas sucrose 
under similar conditions had the reverse effect on the same subjects (33). 
Antar and Ohlson (34) confirmed this in both men and women but 
Macdonald (35,36) found no rise in the total serum lipid of pre- and 
post-menopausal women in response to dietary sucrose. In a series of 
fat-free diets given to men for 5 days,no change in the level of total 
serum lipids was found when the dietary carbohydrate was cornstarch or 
sucrose and a fall was observed when a partial hydrolyzate of starch, 
maltose or glucose was the dietary carbohydrate (37). It must be 
remembered that the total lipid concentration in the serum is composed
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of several fractions whose levels can be altered independently of 
one another, and that the serum is only a reflection of metabolites 
"in transit" and gives but little idea of the contribution of the 
various metabolically active sites to the serum mix (38).
(li) The effect of diet on cholesterol levels
Macdonald (38) gives a detailed history of the investigations 
of the effect of different carbohydrates on the cholesterol levels in 
animals. He draws the conclusion that there are too many variables 
which seem to be important in the regulation of serum cholesterol.
These include the species of animal (cf 39) and within a species; the 
age and sex of the animal; the extent of cholesterol in the experimental 
diet; the extent and type of lipid in the diet; weight changes (which
are known to influence serum cholesterol concentrations (40); and the
number of meals ingested during 24 hours. Thus in animals, dietary 
carbohydrate can alter the serum cholesterol level but it is probably 
of minor importance.
Manning and Clarkson (41) were able to induce atherosclerosis 
in test cats fed a high fat cholesterolvcontaining diet for 12 months; 
no atherosclerosis was seen in the control cats fed the same diet 
without added cholesterol. Test cats did not develop sustained hyper­
cholesterolemia when the diet contained 0.5% cholesterol. However, 
marked hypercholesterolemia occurred when the added cholesterol content 
was increased to 2%.
Luginbuhl et al (42) using 10 female pigs (12-14 years old) from 
breeding stock which had been a consistent source of animals with more 
or less advanced atherosclerosis of aortas, extra-mural coronary, 
cerebral artéries and other sites, separated them into two groups of 5 
animals. One was fed the customary garbage ration and the other a 
garbage ration supplemented by dried egg-yolk in amounts which supplied 
35% of the calorific intake. Egg-yolk feeding for 10 to 14 months was 
associated with significantly less aortic and extra-mural coronary 
atherosclerosis. Intramural coronary and cerebral atherosclerosis was 
not measurably different in the two groups. They concluded that factors 
other than egg-yolk feeding are responsible for the progress of athero­
sclerosis.
As serum-cholesterol concentration can be changed by the type of
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carbohydrate ingested, the mechanisms responsible require more investi­
gation. The results of Seethanathan and Kurup (43) clearly indicated 
that carbohydrate metabolism, both glycolysis and glycogen synthesis, 
is affected in rats fed a high fat-high cholesterol (hypercholesterol- 
aemic) diet.
Fairhurst and Waterhouse (44) observed what appears to be a fat- 
wiihdrawal effect on cholesterol esters in man. In a diet containing 
60-76% of calories as partially hydrolyzed starch the level of cholesterol 
ester fell, due mainly to a fall in cholesterol linoleate.
Pleshkor (45) suggests that the rapid rate of absorption of 
sucrose from the gastrointestinal tract was responsible for the elevation 
in the serum cholesterol of 30 patients with atherosclerosis of the 
coronary vessels, fed on extra dietary regime of 50g. sucrose/day.
Winitz et al (4^) observed a fall in the serum cholesterol of 18 healthy 
subjects on a fat-free diet with glucose as the sole carbohydrate, but 
when 25% of the glucose was replaced by sucrose the serum cholesterol 
level again rose rapidly.
Macdonald and Braithwaite (33) in a study on normal subjects on 
a low-fat diet (22-58g/day) observed a fall in serum cholesterol with 
starch as sole carbohydrate but when this was replaced by sucrose the 
serum cholesterol level rose. In pre- (35) and post-menopausal women 
(36) the serum cholesterol did not rise in response to sucrose.
Macdonald (37) found that cornstarch, partially hydrolyzed starch, 
maltose, and glucose all caused the serum cholesterol level to fall 
after 5 days on a fat-free diet, whereas no significant change was seen 
with the sucrose-containing diet. Fructose as opposed to glucose in a 
similar study did not affect serum cholesterol levels (47).
Dunnigan et al (48) examined the effect of isocaloric exchange 
of dietary starch and sucrose on the serum lipids in 9 middle-aged men. 
These results indicated no change in the serum cholesterol and triglyceride 
levels within the range of starch and sucrose intakes of the normal 
Western diet; they also agreed with their earlier conclusions (49) and 
were similar to the findings of Grande et al (50), Lees (51) and 
Antonis (52). They are at variance with those of Macdonald and Braithwaite 
(33), Groen et al (53) and Antar and Ohlson (34). Changes in serum lipids 
may occur in gross hyperlipaemia which are not evident in normolipaemic
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or even moderately hyperlipaemic subjects, Anderson (54); Grande (55), 
However Nalsmith et al (56) raised the sucrose intake, at the 
expense of starch-rich foods, in the diet of 23 healthy male students 
and found an increase in the plasma•. concentrations of triglycerides, 
total cholesterol and phospholipids at the end of the high-sucrose 
period.
In a normal individual it seems likely that dietary carbohydrate 
can affect the serum cholesterol level only if the diet contains some 
fat, and doubtless the type of fat would have a more marked influence 
on serum cholesterol than the type of dietary carbohydrate (38).
(iii) Glyceride and phospholipid level changes through dietary 
modification.
Lyon et al (57) found that oral glucose resulted in an increase 
in the capacity of the liver to convert added acetate to fatty acids 
in fats. Bragdon et al (58) found a decrease of serum glycerides 1 hr. 
after the acute feeding of sucrose, and similar findings were separated 
after intravenous glucose in man (59). 35-40 days after rats had eaten
a diet containing potato starch (9%) as the carbohydrate the serum 
glyceride concentration was elevated (60). Macdonald and Roberts (61) 
found no increase in serum glycerides in rats after 12 weeks on a fat-free 
diet containing glucose,fructose or sucrose as the carbohydrate. However 
they found evidence of adaptability in the serum-lipid response to
fructose and sucrose, as opposed to glucose as the dietary carbohydrate.
14Using C-labelled carbohydrate incorporation studies, more dietary
sucrose and fructose than glucose was incorporated into serum glycerides
with time. However, the one unknown factor in incorporation studies is
the pool size. Hence, if as is quite possible, the pool size of fructose
is extremely small compared to that of glucose, the dilution of the
latter may lead to the wrong interpretation regarding rate of incor- 
14poration of C-carbohydrate.
14ColtartandCrossley (62) observed the effects of a C-sucrose 
meal in baboons. Before the sucrose diet the blood fSuctose levels 
following a ^^C-sucrose meal were the same in both male and female baboons, 
an observation similar to that found with man. After 13 weeks on the 
sucrose diet, a ^^C-sucrose meal led to higher levels of blood fructose 
in male baboons than in females, and therefore resulted in greater
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incorporation of fructose into triglyceride in the male animals. This is 
parallel to the situation In men and ^re-menopausal women. Coltart 
et al suggest that this sex difference operates at a level of absorption 
rather than at one of metabolism.
Bailey et al (64) found higher hepatic enzyme activities of those 
enzymes thought to be associated with lipogenesis, in uZ^xsts receiving 
dietary fructose or sucrose than in those fed diet 86,or glucose.
Zakim et al (65) found a greater incorporation of acetate into lipid 
by horaogenates of liver from rats which had been fed a sucrose rich diet 
than from those given a starch rich diet. The results of Bailey et al (64) 
showing an increased enzyme activity produced by fructose and sucrose 
could not be explained by greater intake of the two carbohydrates.
Hill (66) observed that in young rats fructose increased the 
serum phospholipids without elevation of triglyceride, while in mature 
rats hyperglyceridemia was followed by elevation of serum phospholipid.
The increase in serum and liver triglyceride suggests a difference in 
the metabolism of carbohydrate or triglyceride,or both, with age.
During 25 days on a high carbohydrate diet, 7 men showed signifi­
cant falls in serum phospholipid levels when the carbohydrate was starch, 
but no fall when sucrose replaced the starch (33). Young women showed 
a fall in phospholipid concentrations with both starch and sucrose 
diets (35) as did some post-menopausal women (36). Serum phospholipids 
were significantly reduced in both men and women on high-cereal diets 
and increased with a high "simple" carbohydrate diet (34). In 5 
patients with hyperglyceridemia a high sugar intake tended to raise the 
serum phospholipids.whereas carbohydrate as starch lowered the phospholipid 
level (67). 19 male subjects previously on an isocaloric sucrose free
diet exhibited a rise in fasting serum phospholipid levels after resuming 
a surcrose-containing diet (68). At the end of a sucrose enhanced diet 
(at the expense of starch-rich foods) 23 healthy male students showed a 
rise in plasma phospholipid, cholesterol and triglyceride concentrations 
(56).
Chevalier et al (69) showed that dietary fructose, as compared to 
glucose, enhanced lipogenesis from fructose but did not affect lipogenesis 
from glucose or acetate. They found (70) that with weanling and mature 
rats fed a diet containing 70.1% glucose, starch, sucrose, or fructose;
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the dietary fructose or sucrose increased serum triglyceride levels 
in the mature but not in the weanling rats,
Dalderup et al (71) studying the life-span of Wistar strain 
albino rats, found that male animals with 3%Cal/100Cal sucrose in 
their food had a shorter life-span than controls receiving 14,5Cal/ 
lOOCal, whereas the life-span of the females was not affected. They 
repeated the experiment (72) with weanling male animals and found no 
difference between the control animals and those with an extra 
sucrose enhanced diet, thus indicating that there are other factors 
besides the sucrose consumption to be considered.
Adams (73) reported a lower survival rate in BH£ strain rats 
fed a diet containing 25% cooked dried whole egg and 39% sucrose, 
than in rats fed 100% cooked whole egg. Allen Durand et al (74) 
observed the effects of different carbohydrates in rats fed a 25% 
cooked egg diet. Sucrose-fed rats had larger livers at 150 and 350 
days than rats fed cornstarch or glucose. At 150 days of age, sucrose- 
fed BHE rats had 37% total lipid as compared with 30% in the glucose fed 
rats. Vv’istars had 24% total lipid and 21%, respectively, for sucrose and 
glucose fed animals.
Ahrens et al (75) report that in a study on the effect of dietary 
carbohydrate source on the responses of rats of two different ages 
to forced exercise, exercise significantly reduced food intake, body 
weight gain, liver weight, the concentration of lipid and cholesterol 
in the liver, serum insulin level and the fat content of the carcass.
In both studies, among the exercised animals, those fed the diet con­
taining a mixture of starches and sugars commonly found in the human 
diet tended to gain more body fat than those fed a cornstarch diet.
Among the sedentary animals those consuming the cornstarch diet tended 
to gain more body fat than those fed the carbohydrate mixture.
Serum glycerides in man are of considerable interest because 
hyperglyceridemia is closely associated with ischemic heart disease 
(76,77). Marvel (78) found a reduction in serum glyceride levels in 
man after hourly glucose doses for 4 hr. comparable to changes in the 
rat. Swan et al (79) reported a fall in the free fatty acid (FFA) 
concentration in men given lOOg. of glucose, sucrose or starch, the 
level remaining depressed longer with starch than with sucrose or glucose.
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Volunteer prisoners who consumed a low-fat, high-carbohydrate diet
for 39 weeks showed immediate and significant rises in their fasting
serum glycerides, with peak values after 5 weeks on the diet (80).
These high levels then subsided slowly and took 32 weeks before the
glyceride level returned to the base level in some subjects* Gillman 
14et al (81) using C-labelled glucose to discover the origin of the 
serum glycerides found that the activity was confined to the glycerol 
moiety of the glycerides and that the fatty acid was mobilized in the 
depots or synthesised from a precursor other than the labelled glucose. 
Partially hydrolyzed starch (75% total calories) and fruit juice caused 
a marked rise in fasting serum glycerides compared with a high (daily) 
fat diet (82). In the same subjects the fasting FFA was at a lower 
level than the glycerides,
Waterhouse et al (83) suggest that the glyceride pool produced 
by high-carbohydrate feeding is more static than it is under the 
influence of low-calorie or high-fat diets. Sucrose elevated the 
serum glycerides of men on a low-fat high-carbohydrate diet (33).
Maltose and glucose caused a fall in serum glycerides in a fat-free 
diet and sucrose was associated with a significant rise in serum 
glycerides, whereas cornstarch and partially hydrolyzed starch evoked 
DO response (37). Macdonald (47) postulated that the elevation was due 
to the fructose in sucrose.
Bender & Thadani (84) reported depressed lipogenesis in both liver 
and adipose tissue in rats fed sucrose as cf. starch. Hepatic lipo­
genesis differed in different strains of rats. The sucrose effect was 
equally marked in fed and 24 hr. fasted rats. However Delboca et al 
(85) report that fasting leads to a marked impairment of lipogenesis, 
and even in the presence of large amounts of insulin the conversion of 
glucose to fat in adipose tissue cannot be restored to normal values. 
Brice et al (86) confirm that the pattern of eating can influence the 
metabolic response to a diet in man.
Froesch & Ginsburg (87) find that adipose tissue metabolizes 
fructose slightly less rapidly than glucose and independently of it.
Fatty acid synthesis is stimulated above the expected level in the 
presence of both hexoses than with individual hexoses. Insulin 
stimulates fructose uptake only in the absence of glucose.
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Paul et al (88) reported that myocardial infarct or coronary 
disease patients had consumed more sucrose than a control group but 
that the difference was less striking than reported by Yudkin and 
Rodday (89), Evidence suggests (90) that both hypercholesterolaemia 
and hypertriglyceridemia are associated with coronary heart disease, 
and that both lipids should be measured in coronary risk detection.
Mounting evidence indicates that abnormalities in carbohydrate 
metabolism ire in some way associated with ischaemic heart disease. 
Epidemological studies are consistant with such an hypothesis. Thus, 
studies in subjects with chronic coronary heart disease show a high 
incidence of carbohydrate ; intolerance which is not simply due to 
the presence of obesity (91).
Carlson AdBottiger (92) in a follow-up study of 3168 men found 
that the rate of ischaemic heart disease (l.H.D.) increases linearly 
with increasing fasting concentration of plasma-triglycerides and 
plasma cholesterol. Plasma triglycerides and cholesterol are risk 
factors for l.H.D. independent of each other, and a combined elevation 
of these two plasma lipids carries the highest risk for l.H.D.
There is some doubt as to whether fructose is the carbohydrate 
mainly responsible for serum glyceride elevation, Kaufmann et al 
(93) report a transient decrease in serum triglycerides in 11 normal 
subjects and 8 patients with carbohydrate induced hypertriglyceridemia.
4hr. after the fructose load, no significant differences were found 
in peripheral blood levels of fructose, glucose, pyruvate and lactate.
Their results refute the concept that intestinal absorption of fructose 
is abnormal in patients with carbohydrate-induced hypertriglyceridemia.
Walker (94) reached the conclusion that such evidence as is available 
does not incriminate sucrose as the causative agent in coronary heart 
disease (C.H.D.). Bearing in mind the multifactorial aetiology of 
C.H.D. it was questionable whether, within a given context, major 
incrimination of sucrose was possible.
Jourdan (95) found that intravenously injected fructose dis­
appeared more rapidly than glucose from the serum of male baboons than 
from that of female baboons. He (96) also recorded that intravenously 
injected ^^C-fructose was more rapidly incorporated into the glycerides of male
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baboons than female baboons. After glucose injection the specific 
activity in the glycerides was significantly less than after fructose
injection, and no difference between the sexes was detectable.
14C-(U)-fructose was incorporated three times more rapidly 
than ^^C-glucose into the triglyceride-glycerol of 7 patients who had 
had a myocardial infarct (97). The radioactivity of triglyceride 
glycerol was 10-20 times greater than that of triglyceride fatty acids.
Male Wistar rats were fed for 7 months on a diet containing 72% 
fructose, glucose or starch and they were then fasted for IS hr. and 
given an intraperitoneal injection of 2.5g. fructose plus 2.5g. glucose 
per kilogram body weight. The animals were then either killed immediately 
or 30 min. after injection. These experiments showed that the fructose 
diet produced the poorest growth, but animals had the heaviest livers with 
high nitrogen contents. The cholesterol blood level produced by fructose 
was significantly higher than that of the animals on the other diets.
The concentration profiles of the metabolites in the livers after fasting 
and after receiving the fructose/glucose injection showed that the 
fructose fed animals were best adapted for rapid metabolism of this 
monosaccharide and that the livers of these animals contained most a- 
glycerophosphate (98).
Hill et al (99) fed rats with glucose or fructose as sole carbo­
hydrate for 3 days and then examined their response to orally administered 
glucose (glucose tolerance test). In the case of the fructose-fed * 
animals there was an impaired capacity to utilize glucose.
The glucose tolerance (G.T.) curves in the fructose-fed rats 
resembled those observed with fasted (96hr.) rats. Their evidence indi­
cated that the decrease in G.T. observed in the fructose-fed animals was 
the result of decreased liver glucokinase activity. These findings were 
considered to be a manifestation of enzymic adaptation to diet.
Inverted intestinal sacs of the guinea pig, but not of the rat, 
convert fructose to glucose during its passage through the intestinal 
wall (100). Ginsburg and Hera (100) conclude that in the guinea pig 
the conversion is mediated, as in the liver, by fructose 1-phosphate 
and triose phosphate intermediates and that the inability of the rat 
intestine to convert fructose to glucose is due to the absence of 
glucose-6-phosphatase (see scheme).
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Fructose to Glucose Conversion in Rat Liver.
Pyruvate
Ballard (101) showed that in liver from fetal rats younger than
14 1420 days, glucose is formed from both 1- C and 6- C-fructose without 
cleavage of the molecule by the aldolase reaction. The rate of glucose 
formation from fructose in the fetuses is approximately half that of 
the adult liver rate, and the direct conversion is not via sorbitol as 
in seminal vesicles. Liver slices incubated with ^^C-(U)-fructose gave 
similar intermediate products (refer scheme) whether from liver of 
13-day foetal, newborn or adult rats.
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Ballard and Oliver (102) report that the activity of 
fructokinase (ketohexokinase) is very low, or even absent (103) 
in fetal rat liver, and that the rate of incorporation of fructose 
into giycogen Is low in liver slices from fetal rats (104). Walker 
(105) suggests that fructokinase reaches adult levels of activity 
7-10 days after birth.
Fructokinase develops after birth in both fructogenic and 
non-fructogenic species and this may represent another example of 
an enzyme responding to hormonal changes occurring as a result of 
parturition (106).
In a study of jejunal enzymes (107) fructose had a specific 
adaptive effect upon fructokinase (B.C.2.7,1.3) and fructose 1- 
phosphate aldolase, whilst glucose exerts its adaptive effect upon 
hexokinase and glucokinase. Fructose 1,6-diphosphate aldolase activity 
is increased by sucrose, fructose, and glucose. Fructose had little 
effect on hexokinase, glucokinase and aldose reductase whereas glucose 
caused a maximal change in these enzymes. Sucrose, except for 
fructose 1,6-diphosphate aldolase changes, gave results intermediate 
between fructose and glucose.
Tlie addition of calories in the form of casein to the diet of 
fasted rats caused a non-specific increase In the activity of all 
jejunal glycolytic enzymes studied. The changes in the rat jejunal 
glycolytic enzymes due to diet reflect those in rat liver.
The rate of incorporation of fructose into plasma and liver 
lipids of guinea pigs was 4 to 6 times that of glucose after intra- 
peritoneal or oral administration (108).
landau et al (109) found that in subjects without hereditary 
fructose intolerance (HFI-a disease characterized by a genetic deficiency 
of fructose 1-phosphate aldolase) the conversion of fructose to glucose 
appeared to be solely through Fructose 1-phosphate; hence in these 
subjects, and presumably in man in general, fructose is not converted 
via sorbitol to glucose in the liver.
A large increase of liver fructose 1-phosphate was reported after 
a large intraperitoneal injection of fructose (110). This is inter­
preted as the result of the inadequacy of fructose 1-phosphate aldolase 
activity to complement fructokinase activity and hence the aldolase is
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a limiting factor in this pathway. It is suggested that the hexo­
kinase route predominates when the system is flooded with fructose, 
whereas fructokinase is more active when fructose levels are low.
Muntz and Vanko (111) observing the effects of intrapartally 
injected 1-^^C and 6-^^C fructose found appreciable amounts of a- 
glycerophosphate derived from both and of the fructose. This 
supports the view that glyceraldehyde is rapidly converted to a- 
glycerophosphate after fructose-1-phosphate scission. Unlabelled 
glyceraldehyde injected together with fructose did not reduce the 
label appearing in the products isolated. However, as aldehydes are 
particularly liable to isomerization and dehydration, no significant 
emphasis should be placed on this observation (112-115).
One third of the men in a sample study given a diet high in 
sucrose developed an increase in the immunoreactive insulin level in 
the blood (116). In the same men this was accompanied by a considerable 
increase in weight and increase in platelet adhesiveness. It has been 
established that the increase of liver size in rats induced by the 
substitution of sucrose for starch is caused by an increase in the 
number of cells, or at least in the number of nuclei. With fructose 
instead of starch, the effect is due to an increase in both cell 
number and cell size (117).
Insulin injected into rats has been shown to increase thé 
deposition of lipid into the aortic wall (118).
The fact that only a proportion of men show "sucrose-induced 
hyperinsulinlsra" suggests that only certain people may be susceptible 
to the effects of sucrose in producing atherosclerotic disease (119).
Naismith et al (56) conclude that the hyperlipedemia (expressed 
as elevated plasmatriglycerides, total cholesterol and phospholipids) 
which resulted from the consumption of sucrose-rich diets was induced 
by sucrose itself and not by any change in voluntary calorie intake. 
Roberts (120) showed that a slight fall in fasting serum glyceride 
concentrations occurred during a sucrose-free period in 19 male subjects, 
but there was a significant rise in the glyceride concentration when the 
sucrose diet was resumed. This reached a peak at 8 weeks, followed by a 
return to the pre-dietary level over the following 16 weeks* Serum 
phospholipid rose after resuming the sucrose-containing diet, but there
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were not significant changes in weight or serum cholesterol.
Sunflower-seed oil in the diet produced a significant fall
in the fasting serum triglyceride, irrespective of the type of 
carbohydrate ingested or the sex of the individual (121). In men, 
cream caused a significant rise in fasting serum triglyceride when 
fed with fructose-starch or glucose-starch carbohydrate mixtures, 
but not with fructose-glucose mixtures. In women, cream was not 
associated with any significant change in fasting serum triglyceride 
levels.
An increase in the activity of fatty acid synthetase in male 
rats on diets of sucrose and fructose as opposed to corn starch, 
maltose or glucose has been reported (122).
Chevalier et al (69) suggest that a diet containing a high 
percentage of fructose causes a shift in the site of lipid synthesis 
from adipose tissue to the liver. Thus, while fatty acid synthesis 
in adipose tissue of the fructose-fed animals decreased,enzyme 
synthesis in liver increased.
o-Glycerophosphate stimulated fatty acid synthesis in vitro
(123). Glucose and fructose in normal animals, and fructose in
diabetic animals that lack insulin, produce a substance that stimu­
lates the production of enzymes involved in fatty acid synthesis (124). 
The substance may be a-glycerophosphate which serves to remove a feed­
back inhibitor such as long chain acyl-CoA. This in turn could lead 
to the derepression of synthesis of these enzymes. Alternatively, 
but less likely, a-glycerophosphate may act as an inducer.
Zakim et al (65) found a higher concentration offa-glycero- 
phosphate in the livers of rats fed a normal **purina" chow diet than 
with a high carbohydrate diet. In contrast, the amount of fatty acids 
synthesized from 1-^^C acetate by liver slices in chow fed animals 
was less than T/io^h of that from tissues from carbohydrate-fed animals, 
Comparing concentrations of a-glycerophosphate the highest a-glycero­
phosphate concentration was present in the chow fed group and was 
associated with the lowest incorporation of isotope into fatty acids. 
a-Glycerophosphate concentration in rats fed high carbohydrate diets 
were essentially the same in all groups. These experiments suggest 
that contrary to what might be expected from results with systems
27
In vitro (123-123), the hepatic concentration of a-glycerophosphate 
does not correlate directly with fatty acid synthesis. It is possible 
that increased fatty acid synthesis removes a-glycerophosphate as 
glyceride and a-glycerophosphate accumulates where fatty acid synthesis 
is primarily decreased. a-Glycerophosphate then appears to play a 
passive rather than an active role in fatty acid synthesis. Under 
some circumstances a low concentration of a-glycerophosphate could 
limit the rate of fatty acid synthesis, a high a-glycerophosphate 
concentration does not seem to be a sufficient stimulus for increasing 
hepatic lipogenesis. It seems, therefore, that carbohydrate induction 
of fatty acid synthesis must be explained other than by the formation 
of an increased concentration of a-glycerophosphate.
Thus,it has been shown that fructose causes an increase of 
hepatic fatty acid synthesis and that fructose metabolism leads to an 
increased concentration of a-glycerophosphate in rat liver. These 
increased concentrations of fatty acids and a-glycerophosphate would 
presumably lead to increased triglyceride synthesis.
A comparison of pre-menopausal women on a low-fat diet containing 
either cornstarch or sucrose showed that with the latter carbohydrate 
a fall in serum glycerides occurred (33). In similar experiments with 
men sucrose was associated with a rise in serum glycerides (33), 
similarly, post-menopausal women on the sucrose diet exhibited an 
increase in serum glycerides (36). Macdonald (47) found that men and 
post-menopausal women on a fat free diet including fructose exhibited 
a rise in serum glycerides, whereas in pre-mencpausal women there was 
a fall in serum glycerides. Jourdan (96) reports a greater incor­
poration of injected fructose into glyceride in male than in female 
baboons. The incorporation of glucose into glycerides in these animals 
was significantly less than in the case of fructose, and no difference 
between sexes was detectable in this instance.
The influence of ihe subject's sex on dietary carbohydrate lipid 
interrelationships is in accord with the incidence of ischemic heart 
disease, namely a high incidence in men and post-menopausal women and 
a low incidence in pre-menopausal women. The fact that men and post­
menopausal women show similar glyceride responses would suggest that 
estrogens or progesterone, or both are influencing the metabolic handling
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of dietary fructose (38).
Reinke et al (126) studied 10 female subjects and showed that 
during the luteal phase of the menstrual cycle (le. at the highest 
progesterone level) there was a statistically significant increase 
of free fatty acids found in the blood which was accompanied by a 
distinct rise in free glycerol. Seng et al (127) found that with 
females using hormonal contraceptives, blood levels of glyceride- 
glycerol and triglycerides were significantly augmented. The same 
results were obtained in principle, when they investigated late 
pregnancies (128). Combined estrogen/progestagen oral contraceptives 
give rise to increased fasting serum triglyceride and, to a lesser 
extent, increased fasting serum cholesterol levels (129-133),
Elevated mean fasting serum-triglyceride levels were reported in women 
on all oral contraceptive preparations (134), the effect being greater 
with increasing estrogen content of the pill. The most estrogenic 
pills gave the highest triglyceride values, and those with the most 
progestagen gave the highest cholesterol values.
Several reports show no significant effect on serum-lipid 
levels in men receiving progesterone (135-137), whilst very small 
amounts of orally active androgens can reverse the estrogenic effect 
on serum cholesterol and lipoproteins (137), Since the 19-nor- 
steroids (synthetic progestagens) used in oral contraceptives are 
closely re ated chemically to orally active androgens, an effect of 
such progestagens on serum-cholesterol is not unexpected (134).
Wynn et al (133) showed that the changes in serum lipids and lipo­
proteins produced by oral contraceptives resemble the pattern des­
cribed by Fredrickson as typeflV hyperlipoproteinemia (138), There 
is as yet no agreement that there is a direct connection between 
type-IV hyperlipoproteinemia and the accelerated development of athero­
sclerosis but there is evidence of a positive association (139-143).
Most of this work has been carried out on males, but since 
oral contraceptives tend to change the lipoprotein pattern of pre­
menopausal women to one resembling that of men and post-menopausal 
woimen, the finding# with men are indeed relevant. Tendencies towards 
obesity and impaired glucose tolerance, which are additional factors 
in the development of atherosclerosis, should be carefully considered
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since both are associated with the use of oral contraceptives (144)#
A study of 20 surgically castrated women and 65 female 
controls suggest that women who have been castrated for at least 5 
years have no mot* coronary atherosclerosis than their ovary bearing, 
age-matched peers (145) and that castration does not adversely 
influence the risk of coronary artery disease created by coronary 
risk factors# However, Renaud (146) found that Premarin (a conju­
gated estrogen) when added to the diets of rats fed a butter-rich 
hyperlipemic diet, was effective in reducing both the serum cholest­
erol and triglyceride levels, and the severity of the atherosclerotic 
lesions# The lower dosage used in these experiments was the most 
effective in prolonging coagulation and in preventing thrombosis#
Vdien a higher dosage was used, however, a marked increase in the 
plasma corticosterone level and a decreased serum albumin level was 
observed#
Cherondache and Blinstruh (147) in a study of 240 elderly 
subjects (age range 63 to 95 years) reported that women showed a 
higher incidence of coronary artery disease than the men# In the 
atherosclerotic patients there was a high concentration of total 
serum cholesterol and a lower level of cholesterol-esterifying 
activity than in the healthy elderly subjects* These differences are 
more significant in women than in men#
With oral contraceptives an increased platelet adhesiveness 
has been described in a small number of patients (143)# In another 
investigation (149) platelet behaviour in women receiving oral con­
traceptives resembled that of patients with arterial disease, in 
that there was an increase of platelet sensitivity to adenosine 
diphosphate# Cutts (150) found that in some cases (12%) a direct 
platelet effect on arterial walls could be produced experimentally 
by administering estrogens to a group of rats*
Despite the above evidence^the Framingham study (151) suggests 
that clinical coronary heart disease may be at least 10 times more 
frequent in men than in pre-menopausal women of a similar age group, 
and Stamler (152) has summarized clinical and autopsy evidence which 
strongly suggests that estrogen has a protective effect against heart 
disease# Experimentally, a decreased incidence of cholesterol-
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induced coronary atherosclerosis in chicks receiving estrogen is 
well established (153).
It is paradoxical that on the one hand a positive, relation­
ship between estrogen-containing oral contraceptives and myocardial 
infarction exists and on the other hand there is evidence to suggest 
a role for estrogens in guarding women against infarction. The 
63q)lanation may be that normally estrogen is a factor in preventing 
or retarding the atherosclerotic process but that it accelerates 
thrombogenesis and resultant myocardial infarction in the relatively 
rare susceptible group of individuals.
Certain clinical trials with estrogen appear to substantiate 
this explanation. Robinson et al (154) treated 57 survivors of 
myocardial infarction with high doses of estrogens and found a 38 
per cent increase of new cardiovascular events. They also found a 
persistent lowering of total serum cholesterol and the ratio of 
cholesterol to phospholipid. In a study of patients with cerebral 
vascular disease a higher incidence of cerebral and myocardial 
thrombotic events werefound in the group treated with estrogens (155). 
Stamler et al (152), however, concluded that estrogen therapy is 
beneficial in long-term survival of patients with coronary heart 
disease, despite the une^ectedly high incidence of fatal and non- 
fatal cardiovascular, renal and thromboembolic complications of 
recent survivors of myocardial infarction receiving a high dose 
(lOmg. daily) of estrogen.
(c) Population distribution. Although populations from various 
countries have widely diverging incidence rates (12-14), the athero­
sclerotic disease process in all susceptible individuals at the time 
of infarction is of similar proportions. This same finding holds 
true when one compares the coronary arteries in young and old persons 
who have had a myocardial infarction, hhen an infarct is present; 
the amount and gross distribution of the atherosclerosis the same 
in the young and older hearts (10)#
(d) Extent of Atherosclerosis. Although the incidence of myocardial 
infarction increases with the amount of atherosclerosis in the coronary 
arteries, at any level of atherosclerosis only a proportion of the 
hearts will have developed an infarct;less than 50% of acute myocardial
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infarctions are associated with fresh thrombi in the coronary arteries. 
The exact sequence leading to muscle death still has to be determined. 
Coronary atherosclerosis gives the setting in which muscle death be­
comes more likely. It is clearly not the entire cause.
(e) Hypertension. The pressure in the arterial tree (arteries around 
the heart) je hypertension,accelerates arterial disease in man (4, 156- 
160) and in cholesterol,or fat-fed animals (161,162). In general, the 
influence of hypertension is more pronounced in diseases accompanied
by hyperlipddemia, but arterial disease is observed even in the absence 
of elevation of serum lipids.
(f) Diabetes. The increased incidence of myocardial infarction among 
diabetic patients is well recognised (163-165).
(g) Smoking and Obesity. In males, the incidence rate of coronary 
heart disease (C.H.D.) in white non-cigarette smokers was 52.7/1000 
and among blacks, 9.8/1000; among white cigarette smokers the rate was 
101/1000 but in blacks only 32.5/1000. The incidence rate of C.H.D. 
increased with increasing obesity, and smokers run a substantial risk 
of developing C.H.D. increasing with increase in overweight (166).
(h) Physical Activity. The relationship between physical activity
and morbidity or mortality from C.H.D. remains a subject of considerable 
controversy. Despite extensive research on the subject (167-182), there 
is no concensus as to whether sustained physical activity is protective 
against C.H.D. Cassel et al (183) in a seven-year follow up study of 
a county population put forward the proposition, based on their own 
observations and those of other workers, that there was a modest 
inverse relationship between physical activity and either the incidence 
prevalence of, mortality from C.H.D. (171,172,177,181), and that there 
was little evidence (178,179,182) to suggest that physical activity may 
be protective against C.H.D. above some critical threshold value.
Two other reports (184,185) state that there is no important 
difference in either incidence of, ©r mortality from C.H.D. between 
active and sedentary men working in the same industry, even though 
the active men expend over 50% more calories than the sedentary. This 
would suggest that under such circumstances the threshold would have 
to be greater than 50% above the caloric expenditure of sedentary 
industrial workers. Cassel et al (183) conclude that the suggestion
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by Rose et al (182) that physical activity leads to an increased 
caliber of the coronary vessels thus making atherosclerosis less 
consequential, is consistent with the known facts and may provide 
a plausible biological explanation for the role of physical activity* 
That atherosclerosis has many possible causes is very evident from 
the information already presented. That the dietary regimen is of 
crucial importance in the etiology of the disease is also evident.
Elevated levels of plasma cholesterol certainly appear to be 
a fairly accurate indicator of incidence prevalence for C.H.D., more 
so as cholesterol appears as a major component of the fat content of 
the arterial plaques in the more advanced stages of the disease.
Triglyceride, however, is present in greater proportions in 
the arterial plaques in the earlier stages of the atherosclerosis 
disease process in the coronary arteries. As sucrose and fructose 
are readily converted to triglyceride in the liver, the presence of 
the di- and mono-saccharide in the diet is of importance. The increase 
of serum glycerides in men after fructose ingestion, not observed in 
pre-menopausal women, is similar to the incidence prevalence of C.H.D. 
to which the male sex is more prone. It would appear therefore,that 
a sex difference in the metabolism of sucrose might be an important 
factor in the etiology of C.H.D.
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Sucrose Metabolism in the Intestine and Liver
Carbohydrates, proteins and lipids are the three major basic 
constituents of the human diet. The proportions of different carbohy­
drates in the diet have been changing fairly rapidly in the more 
affluent countries in the last hundred years, with the result that 
sucrose is assuming more prominence at the expense of starch. A 
national food survey in the United Kingdom in 1967 indicated the 
following approximate carbohydrate contributionsto the daily diet;
Starch 175g; sucrose 140g; lactose 20g; other sugars (almost entirely 
fructose and glucose) 15g; (186).
Dietary sucrose is hydrolyzed by the enzyme sucrase ( ^ ^  
fructofuranosidase; B.C. 3.2.1.26) in the brush border of the intestinal 
mucosa to give equal proportions of glucose and fructose. The main site 
of sucrase activity is located in the mucosal cells of the small intes­
tine and not in the gut lumen (187-191). The majority of the disaccha­
ride is not hydrolyzed in the intestine, but is, instead, absorbed 
intact, and then hydrolysed by the intracellular enzyme (190).
Sucrase appears to be induced by a sucrose rich diet (192).
Gray and Ingelfinger (193) found the same intestinal absorption 
rates for fructose and glucose no matter whether sucrose or an equiva­
lent mixture of fructose plus glucose was fed.
This means that it is not the individual absorption rates of 
glucose and fructose but the hydrolysis of sucrose which determines 
the letter's rate of absorption.
There is interconversion of glucose to fructose via glucitol 
in the seminal vesicles (194) but this has not been reported to occur 
in the intestine or liver (195,196). The main metabolic pathways for 
glucose and fructose are shown in Fig.2. Major differences in the 
pathways can be found at the phosphorylation and triose formation stages,
In the metabolism of glucose in liver the first stage is the 
phosphorylation of the hexose to glucose 6-phosphate by hexokinase (ATP: 
D-hexose 6-phosphotransferase; B.C. 2.7.1.1) or glucokinase (ATP: D- 
glucose 6-phosphotransferase; B.C. 2.7.1.2).
Hexokinase is relatively unspecific and utilizes ATP as a 
phosphate donor converting a number of different hexoses to the corres­
ponding 6-phospliates.
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The Enzymes Involved in Sucrose Metabolism
( 1) Sucrase or Invertase (B.C.3.2.1.26)
( 2) Hexokinase (E.C.2.7.1.1.)
( 3) Glucokinase (B.C.2.7.1.2)
( 4) Glucose 6-phosphatase (B.C.3.1,3.9)
( 5) Glucosephosphate isoraerase (E.C.5,3.1.9)
( 6) Phosphofructokinase (E.C.2.7,1,11)
( 7) Hexose diphosphatase (E.C.3.1.3.11)
( 8) Fructose 1,6-diphosphate aldolase (B.C.4.1*2.b)
( 9) Triosephosphate Isomerase (E.C.5.3.1.1)
(10) Fructokinase or Ketohexokinase (E.C.2.7.1.3)
(11) Fructose 1-Phosphate aldolase (.E.C.4.1.2.7)
(12) Aldehyde dehydrogenase (E.C,1.2.1 3)
(13) Glycerate kinase (.E.C.2.7.1.31)
(14) Glycerol dehydrogenase (E.C.1.1.1.6)
(15) Glycerol kinase (.E.C.2.7,1.30)
(16) Triokinase (E.C.2.7.1.28)
(17) o-Glycerophosphate dehydrogenase (E.C.1.1.18)
(18) Glycerolphosphate acyltransferase (B.C.2.3.1.15)
(19) Glucitol dehydrogenase (E.C.1.1.1.14)
(20) Aldose reductase (E.C.1.1.1,21)
(21) Phosphoglucomutase (E.C.2.7.5.1)
(22) UDPG-pyrophosphorylase (E.C.2.7,7.9)
(23) Glycogen synthetase (E.C.2.4.1.11)
(24) Glucose 6-Phosphate dehydregenase (E.C.1.1.1.49)
(25) Gluconokinase (E.C.2.7.1.12)
(26) Phosphogluconate dehydrogenase (E.C.1.1.1.44)
(27) Transaldolase (E.C.2.2.1.2) and Transketolase (E.C.2.2.1.1)
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This probably occurs by a direct transfer of the phosphoryX 
group from the donor to the acceptor without a phosphoryl-enzyme 
intermediate (196). All enzymes transferring phosphate groups from 
nucleotide triphosphates require Mg^* ions (197). Hexokinase 
activity is controlled by the cellular level of glucose 6-phosphate 
and glucose utilisation is dependent on the removal of this hexose- 
phosphate (198).
Soluble hexokinase is more sensitive to product inhibition 
at low ATP and less sensitive at high ATP concentrations than is the 
mitochondrial enzyme (199). Differential centrifugation and local­
ization techniques have suggested that the bound hexokinase is located 
on the outer mitochondrial membrane (200). However Wilson (201) 
reports an intraparticle location of the enzyme but offers no clear 
physiological interpretation. Appreciable amounts of hexokinase in 
latent form have been reported in the rat (202,203) and guinea pig 
(204), however the metabolic significance is presently unknown.
Grossbard & Schimke (205) report the occurrence of three hexo- 
kinases in various rat tissues. The three enzyme types I (brain and 
kidney), II (skeletal muscle and epididymal fat pad) and III (liver) 
have different electrophoretic and chromatographic properties, as well 
as different low Km values when glucose is used as substrate,are 
similar with respect to pH optimum, molecular weight, hexose and 
nucleotide specificities. Km value for fructose, and the qualitative 
nature of inhibition by ADP and glucose 6-phosphate.
Casein non-carbohydrate diets have been shown to decrease the 
intestinal hexokinase activity in comparison with starved animals (206). 
High fructose diets do not increase hexokinase activity whereas high- 
glucose or sucrose diets increase hexokinase activity but only in 
comparison with the casein-fed animals.
Rat hepatic hexokinase activity increases after weaning (21 day 
old animals) to a maximum at 40-45 days before falling to pre-weaning 
values (70 days). Sucrose has little effect on this enzyme (207).
Rat kidney hexokinase activity increases after birth to a 
maximum at 30 days of age, thereafter falling to reach adult values at 
50 days (208). These results are an extension of the findings of 
Sydow (209).
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Glucokinase is a much more specific enzyme and appears to be 
restricted to the liver (210).
The enzyme from rat liver which has been purified (211) does
show absolute specificity for glucose as substrate. Hence 2-deoxy
glucose and mannose are both phosphorylated but they exhibit high Km
values. However,in view of the low Km value,glucose is the only
substrate likely to be phosphorylated by glucokinase under physiological
conditions. The enzyme is inhibited by high concentrations of glucose
6-phosphate but glucokinase does not possess the special allosteric
site for inhibition by product as do many mammalian hexokinases. ADP
2*is an inhibitor but here the degree of inhibition depends on the Mg 
ion concentration.
Sols et al (212) report that glucokinase appears in rat liver 
only some time after birth and its presence in the adult liver depends 
on induction by insulin. Insulin induction of glucokinase has been 
confirmed (213-215) and as a corollary the kinase activity in rats 
depends on the amount of glucose present in the diet (216). Glucokinase 
activity is decreased on feeding rats a fructose diet; this may be 
interpreted as a consequence of the inability of fructose to stimulate 
the release of insulin from the pancreas (217, 218).
Glucose 6-phosphate can be reconverted to glucose by glucose 6- 
phosphatase (^(glucose 6-phosphate phosphohydrolase E.C. 3.1.3.9) or it 
can be isomerized to fructose 6-phosphate by glucosephosphate isomerase 
(p-^lucose 6-phosphate ketolisometase E.C. 5.3.1.9).
Glucose 6-phosphatase catalyzes the following reaction;
D-Glucose 6-phosphate D-glucose 4 orthophosphate.
In rat liver, enzyme activity is localized in the endoplasmic 
reticulum and nuclear envelope; the other cytoplasmic organelles possess 
no activity (219-223).
Inorganic pyrophosphate-glucose phosphotransferase activity 
appears to be identical with glucose-6-phosphatase, eg.
Glucose ♦ PP^— > Glucose-6-phosphate ♦ P^, and this same 
protein also appears to possess inorganic pyrophosphatase activity.
In rats there is a slow build up of hepatic activity to 18 days 
gestation followed by a marked increase at term. Thyroxine, glucagon.
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epinephrine and cyclic-AMP are known to cause premature development 
of activity (224-227).
Rats fed diets in which protein, fat, galactose or fructose is 
substituted for a direct glucose source show a marked increase in 
liver glucose 6-phosphatase specific activity. This response to diets 
low in glucose is a metabolic adaptation expressed through increased 
synthesis of an enzyme directly involved in glucose biosynthesis (228).
Glucosephosphate isomerase catalyses the interconversion of 
glucose 6-phosphate to fructose 6-phosphate. No substrates other than 
these two phosphates are known (229). The enzyme is present in most 
tissues at very high levels (230) and has been purified from bovine 
mammary gland: this isomerase has a molecular weight of 48,000 (231).
The Michaelis constants for both hexose phosphates are very small 
(jfructose 6-phosphate, 1.0 x 10* M; (glucose 6-phosphate 3.0 x 10* M).
This results from the fact that the reaction velocity with substrate 
excess is approximately the same in both directions, even though 
equilibrium substantially favours glucose 6-phosphate formation (230).
In the case of isomerases from rabbit brain and muscle, and human 
erythrocytes, ATP, phosphoenol pyruvate, 6-phosphogluconate, phosphate, 
pyrophosphate and high concentrations of ions are known inhibitors
(229,230).
Fructose 6-phosphate may be converted to fructose 1,6-diphosphatt 
by phosphofructokinase (AT? D-fructose 6-phosphate 6-phosphotransferase; 
E.C. 2.7.1.11) as follows:
Fructose 6-phosphate ♦ ATPfructose 1,6-diphosphate + ADP.
This enzyme has quaternary structure and is regulated by a variety 
of agents, including substrates, substrate analogues, AMP and cyclic 
3*,5*-AMP (232,233). The catalytic activity of the enzyme is inhibited 
by high concentrations of ATP, which specifically inhibit the binding 
of fructose 6-phosphate and this inhibition is reversed by inorganic 
phosphate. Citrate, a structurally unrelated compound, increases the 
affinity of the enzyme for ATP and decreases its affinity for AMP and 
fructose 6-phosphate (234).
Phosphofructokinase from brain and muscle is inhibited in vitro 
by phosphocreatine, 3-phosphoglycerate, phosphoenolpyruvate, 2-phospho- 
glycerate and 2,3-diphosphoglycerate (235). This inhibition is most
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pronounced at neutral pH values, in the presence of inhibitory levels 
of ATP and non-activating fructose 6-phosphate levels and in vivo the 
whole phenomenon is probably important for the regulation of glycolysis.
Paetkau and Lardy (236) have purified rabbit muscle phospho­
fructokinase and shown that it requires K* ions for maximal activity and 
is Inactive at pH 7 unless the Mg^* ion concentration exceeds the total 
ATP concentration. Enzymic activity is proportional to the number of 
reduced SH groups and is reversibly lost by oxidation. The smallest
5
fully active form of the enzyme has a molecular weight of 3.8 x 10 and 
can be reversibly dissociated into units one-half or one-quarter this size.
Fructose 1,6-diphosphatase (D-fructose 1,6-diphosphate 1-phospho- 
hydrolase; E.C. 3.1.3.11) with ions as cofactor will catalyse the
reconversion of fructose 1,6-diphosphate to fructose 6-phosphate.
This enzymic step is presumed to be obligatory for glyconeo- 
genesis in order to bypass the highly exergonic phosphofructokinase 
reaction (237).
Fructose 1,6-diphosphatase is inhibited by AMP, the degree of 
inhibition depending upon the concentration of fructose 1,6-diphosphate 
and ATP. At low fructose 1,6-diphosphate concentrations AMP is less 
inhibitory than at higher concentrations. The inhibition by AMP is 
partially reversed by ATP (238). The AMP/ATP ratio in the cells must, 
therefore, effect a delicate control of the fructose 6-phosphate- 
fructose 1,6-diphosphate interconversion by regulating both phospho­
fructokinase and fructose 1,6-diphosphatase,
The -lenzyme aldolase (Fructose 1,6-diphosphate D-glyceraldehyde 
3-phosphate lyase; E.C. 4.1.2.b) will cleave fructose 1,6-diphosphate 
yielding dihydroxyacetone phosphate and glyceraldehyde 3-phosphate as 
followsj
CHL-O-P
I "
P - O  -CH
OH
OH
OH H
0=0
CHL-O-P
I ^
Fructose 1,6-diphosphate HC-OH
C
Dihydroxy Glyceraldehyde.
acetonephosphate 3-phosphate.
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Claims have been made that the aldolase activities of liver with 
fructose 1,6-diphosphate and fructose 1-phosphate are due to different 
enzymes (239) although the studies of other investigators indicate 
that a single enzyme can account for both activities (240-244).
Crystalline fructose diphosphate aldolase preparations obtained 
from rabbit muscle and bovine liver exhibit different enzyme kinetics 
(245). However, in spite of these distinctive catalytic properties the 
two protein molecules have similar molecular weights and numbers of 
sulphydryl groups (243,246-248), although they differ in amino acid 
composition (240) and immunochemical properties (101,240-244,249-254). 
Treatment of the muscle enzyme with carboxypeptidase yields a protein 
which has a similar substrate specificity and catalytic activity to the 
liver enzyme (251).
Rabbit muscle aldolase has a molecular weight of 160,000, and 
in cold alkaline borate solution dissociates into 4 sub-units of 
molecular weight 41,400-42,000 (254).
Normal and carboxypeptidase-treated muscle and liver aldolases 
are competitively inhibited by fructose 6-phosphate (Ij1-2mM) with 
fructose 1,6-diphosphate as substrate (241).
In vitro rat muscle aldolase is competitively inhibited by ATP> 
2+ADP> AMP, and Mg ions reverse the ATP inhibition. However liver 
aldolase is inhibited by AMP» ADP and is not affected by ATP (209).
Liver aldolase activity in female rats is constant in 21-40 day 
old animals, rises to a maximum at 50 days and then falls until 70 days, 
Sucrose produces some elevation of enzyme activity at all these stages 
of development (207).
The two products of fructose 1,6-diphosphate cleavage, dihydroxy­
acetone phosphate and glyceraldehyde 3-phosphate can be interconverted 
by triose phosphate isomerase (D-glyceraldshyde 3-phosphate ketol 
isomerase; B.C. 5.3.1.1);
CH^-O-P CH^-O-P
C=0 r-  ^ H-C-OH
I I
CH^OH C./\ 
H
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This enzymic reaction was a high catalytic activity and is one 
of the connecting links between the main fructose metabolising and 
the gluconeogenic pathways.
22(255,256).
Phosphate ions inhibit the enzyme (255,256).
The first enzymic step in the metabolism of fructose in the liver 
involves fructokinase (ATP; D-Fructose 1-phosphotransferase; E.C.2.7.1.3). 
There is some confusion over the terminology of this enzyme. It is 
referred to as both fructokinase (E.C.2.7.1.3) or ketohexokinase (E.C* 
2.7.1.3), however,in this thesis the former nomenclature will be used.
In the presence of ATP, fructokinase phosphorylates fructose to
fructose-1-phosphate. The enzyme has an absolute requirement for Mg *
2+ions (or Mn ) and is strongly activated by high concentrations (1-2M) 
of K* ions (257,253). p-Chloromercuribenzoate is an inhibitor of fructo4 
kinase which is stable up to 50-55^ (206).
Fructokinase can be assayed in the presence of hexokinase first 
by partially destroying the hexokinase by acid treatment followed by 
inhibition of the remainder with 2-acetamido 2-deoxy-g-glucose (259).
Liver fructokinase acts on the three ketohexoses; fructose, 
sorbose and tagatose (257,260). Aldohexoses and fructose-6-phosphate 
are not phosphorylated. The affinity for fructose is very high , the 
value being < 5 x 10*^M.
Rat liver fructokinase has been purified to a near homogeneous 
state (206).
Fructokinase is not found in fetal rat livers (103) but Ballard dnd 
Oliver (102) suggest that it may be present at a very low level. However, 
Ballard (101) observed high conversion rates of fructose to glucose in 
fetal rat liver which is probably due to the action of hexokinase,an 
enzyme known to be present in neo-natal animals.
Liver fructokinase activity is increased in rats on a fructose- 
enriched diet (99) or when fructose is administered intraperitoneally
(261). Fasting rats lose their enzyme rather rapidly - 50-60% total 
activity remains after a 3-day fasting period (261) Normal fructokinase 
activity in fasted male rats is restored by feeding fructose* recovery 
of activity occurs within a 4- to 8- hr.;, period following a lag of about
42
16 hr., and roughly parallels increase in liver weight. Complete 
recovery occurs after 24 hr. Fructokinase activity of adrenalecto- 
mized rats on a normal diet is the same as the fasting level of normal 
rats and is neither lowered further by fasting nor increased by sub% 
sequent feeding of fructose or glucose (262). Long term feeding of 
fructose to normal rats results in a maintained, considerably higher 
enzyme level than that in animals on a high fat or high protein diet
(262).
The cleavage of fructose 1-phosphate by fructose 1-phosphate 
aldolase (ketose 1-phosphate aldhhyde lyase, É.C. 4.1.2.7) produces 
glyceraldehyde and dihydroxyacetone phosphate.
HOH^C CH^OP CHgOH CH^OP
HCOH + C=0
C CH-OH
/ W ^
The role of this aldolase in the metabolism of fructose 1-phosphate in 
the liver was recognised in 1952 by Hers et al (195,264) and Leuthardt 
et al (265,266). The enzyme may be the same aldolase which reacts with 
fructose 1,6-diphosphate in the glycolytic pathway (240-244).
The reaction with fructose 1-phosphate is freely reversible, 
however the equilibrium favours the fructose ester (263).
Spolter et al (241) reports that the kinetic behaviour of rabbit 
muscle and liver aldolases towards fructose 1-phosphate in the presence 
of glyceraldehyde, a product of the reaction, indicates that the 
cleavage of the phosphate by both native and partially degraded (car­
boxypeptidase-treated) forms of the liver enzyme is an ordered reaction 
in which glyceraldehyde is released before the enzyme-dihydroxyacetone 
phosphate complex is dissociated. With the native or carboxypeptidase- 
treated muscle enzyme it is a random reaction with no obligatory sequence 
in the release of either product from the enzyme.
Fructose 1-phosphate aldolase activity decreases to about one- 
half of its normal total activity when male rats are fasted for 48-72 hr. 
and activity is completely restored in 24 hr. by feeding fructose (262)t 
feeding glucose has a similar effect. As with fructokinase, there is a 
16 hr. lag period on feeding fructose before aldolase activity is 
restored to normal.
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Long term fructose feeding results in considerably higher 
aldolase levels than in the case of high fat or protein diets (262); 
this is again similar to the behaviour of fructokinase.
Alloxan-diabetic rats have similar levels of aldolase to
normal animals,as do fed,adrenalectomized rats. In the latter case 
fasting produces a rapid decrease in activity which is not alleviated 
by subsequent feeding of fructose or glucose. The same pattern was 
found with hypophysectomized as with adrenalectomized rats (262).
Heinz et al (267) report ratios of aldolase activity, measured
with fructose 1,6-diphosphate and with fructose 1-phosphate, of 2.62
(n=5,S.D*=0.24) for rat liver and 1.67 (n=11,S.D=0.16) for human liver. 
These figures indicate that there are differences between the two 
aldolases. This observation is in agreement with those of Anstall, Lapp 
and Trujillo (268) who showed that the aldolase isozyme patterns were 
different in human and rat livers.
Hereditary fructose intolerance (H.F.I.) is due to a lack of 
fructose 1-phosphate aldolase. Children with this condition thrive in 
the absence of a dietary source of fructose, but in the presence of the 
monosaccharide, fructosemia, fructosuria, hypoglycemia^aminoaciduria, 
glycosuria, proteinuria and acidosis may occur (269).
Cain esti Ryman (270) report a high liver glycogen level in a case 
of hereditary fructose intolerance in humans. At necropsy the liver 
enzyme estimations showed that fructose 1-phosphate aldolase activity 
was absent and the fructose 1,6-diphosphate aldolase activity reduced, 
(cjf Hers anclJoas sin (27/1)). Cain and Ryman (270) have questioned whether 
fructose 1-phosphate aldolase and fructose 1,6-diphosphate aldolase 
activities are due to two separate catalytic proteins or whether they 
represent two activities of the same enzyme protein one of which is 
totally, and the other partially, lost in H.F.I.
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Glyceraldehyde is the centre of a metabolic ^crossroads* as shown in 
the figure, (Fig.2a).
Fructose Glucose
I
Glucose-6-P
I
Fructose-6-P
Eihy d r oxy ace t one*,?Fructose-1-P
Fructose-1,6-P
Glycerol Glyceraldehyde-3-P
1,3-P^-Glycerate
Glycerate
I
P-anolpyruvate
1
Pyruvate
Fig. 2a
see Sillero et al (217)
Fructose metabolism in liver and glyceraldehyde "crossroads'# 
a - triokinase; b - aldehyde dehydrogenase; c - c'alcohol dehydrogenase
There are three postulated pathways for the further metabolism 
of glyceraldehyde by the glycolytic pathway* (a) it can be converted to 
glyceraldehyde 3-phosphate by means of a triokinase (195); (b) it can
be converted to 2-P-glycerate via glycerate, the reactions being catalysed 
by aldehyde dehydrogenase (266, 272,273) and glycerate kinase (274-276); 
and (c) an alcohol dehydrogenase (277-279), glycerol kinase (230,231) add 
glycerolphosphate oxidase (232) con together effect dihydroxyacetone 
phosphate production#
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Sillero et >1 (217) on the basis of a study of female rat liver 
enzymes with animals on different regimens of nutrition conclude that 
the triokinase pathway (a) prevails for fructose metabolism. The 
name 'triokinase (ATPiD-glyceraldehyde 3-phosphotransferase; E.C. 2.7.1.28) 
was given to the enzyme which converts D-glyceraldehyde to the corres­
ponding 3-phosphate and dihydroxyacetone to the 1-phosphate (195), in 
the presence of ATP and ions. The rate of phosphorylation is
approximately the same for both triose substrates, neither reaction 
being inhibited by glycerol. L-Glyceraldehyde is not phosphorylated 
by the enzyme^(283).
In human liver, the activity of triokinase is 2.7 units/g. (267) 
therefore direct phosphorylation of ^glyceraldehyde can probably 
occur in this tissue.
A second possibility is that glyceraldehyde can be phosphory­
lated indirectly to a-glycerophosphate by successive reaction with 
alcohol dehydrogenase and glycerol kinase. This is perhaps unlikely, 
however, as there is a low level of the latter enzyme in human liver (267),
Rat liver possesses a significantly lower level of  ^^ -triokinase 
and a higher level of glycerol kinase than the human tissue.
Aldehyde dehydrogenase (Aldehydet NAD (?) oxidoreductase E.C. 1.2.1.3.)* 
This enzyme catalyses the conversion of D-glyceraldehyde to D-glycerate. 
The enzyme oxidizes a number of substrates viz. formaldehyde, 
acetaldehyde and propionaldéhyde. It is a sulphydryl enzyme with a 
sharp pH optimum at 9.3 (284).
The activity of aldehyde dehydrogenase in human liver is three- 
quarters of that found in rat liver (267).
Glyceric acid enters the Emden-Mcyerhof glycolytic pathway after 
phosphorylation to 2-phosphoglycerate which is catalysed by 'glycerate 
Kinase (ATP:D-glycerate 2-phosphotransferase; E.C, 2.7.1.31).
Purified rat liver glycerate kinase is completely inactive
towards L-glycerate and has a Michaelis constant for D-glycerate of
about one-tenth of that found for the horse-liver enzyme (275). Mg^^ ions
2+cannot be replaced by Mn ions, and kinetic studies suggest that an 
ATP-Mg^*-ATP complex could be the substrate for the reaction (285).
Glycerate kinase activities for*human and rat livers were 0.13 u/g 
and 3.19 u/g, respectively, (267). The authors (267) believe that in
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human liver the capacity of the kinase is too low to play any physio­
logical role. If D-glyceraldehyde were oxidized to D-glyceric acid, 
this substrate would accumulate in human liver and escape into the 
blood.
Glycerol Dehydrogenase C(Glycerol:NAD oxidoreductase, E.C.1.1.1.6)
Wolf and Leuthardt (286) reported the presence of NADÎ dependent 
glycerol dehydrogenase in rat- and pig- liver extracts which catalysed 
the reduction of DL-glyceraldehyde to glycerol. The equilibrium for 
this reaction strongly favours glycerol,and dihydroxyacetone is a poor 
substrate for this enzyme.
Moore (279) detected NADP* specific glycerol dehydrogenase in rat 
liver with a total activity one-eighth that of the NAD* dependent 
enzyme. The equilibrium again favours glycerol formation, and the 
enzyme is strongly inhibited by p-mercuribenzoate.
A NADP* specific glyceroldehydrogenase was also found, predomin­
antly in the non-particulte fraction of the cell, in skeletal muscle 
(287). Dihydroxyacetone is reduced at 5% of the rate of D-glyceraldehyde 
by this enzyme. The rate of reaction with NADH is only 10% of that with 
NADPH. The pH optimum stated is 7.0 for D-glyceraldehyde reduction, and 
9,0 for glycerol oxidation. This enzyme has been purified by Karmann 
et al (288) who showed that it has a molecular weight of 34,000- 1000.
NAD*-dependent glycerol dehydrogenase appears to be present only 
in liver whereas the NADP dependent glycerol dehydrogenases are found in 
placenta, liver, kidney, heart, skeletal muscle, small intestine, brain, 
lung and adipose tissue (289). Kinetically, however, there are several 
major differences between the NADP-dependent glycerol dehydrogenases 
from different organs, and they can also be distinguished on the basis of 
inhibition by fluoride (289). Toews (289) suggests that the reaction 
mechanism for skeletal muscle glycerol dehydrogenase is probably an 
ordered mechanism, where the first product leaves the enzyme before the 
addition of the second substrate.
Glycerolkinase (ATP: glycerol phosphotransferase; E.C.2.7.1.30) catalyses 
the reaction.
ATP+Glycerol— >L-glycerol-3-phosphate + ADP
Hers (285) uses the name L-triokinase which describes adequately 
the catalytic properties of the enzyme; the term glycerolkinase is more
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descriptive of its presumed physiological function.
Boblitz and Kennedy (230) purified the rat liver enzyme 170- 
fold and crystallization by Wieland and Suyter (231) gave a 580- 
fold purification.
"Die purified enzyme catalyses the phosphorylation of dihydroxy 
acetone and L-glyceraldehyde twice as fast as that of glycerol. The 
product of this phosphorylation can be acylated in the liver to give 
phosphatidic acids which in turn are further acylated to triglycerides.
Glycerol is a molecule in which the C-2 carbon atom can be 
represented thus#
Cl^OIi lOI^C
iiO
H ^ or 2 H
c
HO
khere the two CH^CH groups are not geometrically equivalent but 
bear a mirror-image relationship to each other. The C-2 carbon actoa 
has been termed a meso-carbon. Enzymes which catalyse - reactions 
involving compounds bearing neso-carbon atoms invariably discriminate 
between the two non equivalent but chemically identical groups. Thus 
the phosphorylation of glycerol by glycerolkinase results exclusively 
in the formation of L-a-glycerophosphate rather than the Dl^mixture 
that would otherwise result (290).
Maximum activity of glycerolkinase is obtained with a ratio 
ATP/Mg^* of 2. ions can replace but Ca^* is inhibitory.
UT? can serve as phosphate donor but the reaction rate is then lialf 
that obtained with AT? (280).
Adelman et al (262) report a ^tal triokinase activity of about 
one-half of normal in male rats that had been fasted for 43-72 hr.
This was also observed by Kampf et at (291). Adelman et al (202) 
report normal levels of triokinase activity in fed adrenalectomized 
rats,and a sharp decrease in activity on fasting,which does not recover 
on subsequent glucose or fructose feeding. Essentially the same pattern 
is found for hypophysectomized as for adrenalectomized rats (282).
However, Kampf et al (291) stated that there was a decrease in enzyme 
activity after adrenalectomy*' but an increase after cortisol substitution 
of the adrenalectomized animal*.
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Triokinase activity,reduced on starvation,is restored to normal 
after feeding fructose for 24 hr; the recovery occurring within a 4- to 
8- hr. period following a lag of about 16 hr. (262). Feeding fat for 
the first 3 days lowers the enzyme activity, but increases it after 
3 days (276). Long term feeding of fructose produces a considerably 
higher level of enzyme in comparison with high fat or high protein 
diets (262). Glucose feeding of previously fasted animals only partially 
restores the enzyme activity (262).
An increase of a-glycerophbsphatéj formation in female ovariecto- 
mized rats given estradiol-17^ was reported by Lea et al (292). 
Significant increases were observed 4hr. after injection with a 
maximum rate occurring after 16 hr. These increases were significantly 
reduced by anti-estrogenic agents and progesterone. Actinomycin and 
cycloheximide resulted in almost completed inhibition of the induced 
increases of a-glycerophosphate.
a-Glycerophosphate is formed either by phosphorylation of 
glycerol by the enzyme glycerokinase or by the action of a NADH - 
requiring g-glycerolphosphate dehydrogenase (L-glycerol 3-phosphate %
NAD oxidoreductase, E.C. 1.1.1.8). This enzyme reacts with dihydroxy­
acetone phosphate in the following way
CH.-O- P
I "
C=0
CH^OH Dihydroxyacetone phosphate
NAD NADH ♦ H*
CH.O- P
I ^
HC-OH
I
CH^OH a-L-glycerophosphate 
A soluble glycerolphosphate dehydrogenase has been reported 
(293) and also a particulate enzyme, localized in the outer part of 
the inner membrane of the mitochondrion (294).
There appears to be a constant ratio in different tissues between 
the activities of mitochondrial a«glycerolphosphate dehydrogenase and 
glyceraldehyde 3-phosphate dehydrogenase, one of the key glycolytic
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enzymes (295), Thus, in highly oxidative tissues such as cardiac 
and red skeletal muscle,the a-glycerolphosphate dehydrogenase 
(mitochondrial) level is low (296% whereas in glycolyzing tissues 
like white skeletal muscle this enzyme is very active (295),
A high activity of mitochondrial a-glycerol phosphate dehy­
drogenase is also found in rat and hampster brown adipose tissue 
(297,295).
It is apparent from Figure 2 that a major difference in the 
metabolism of fructose and glucose is that the former is converted 
to glyceraldehyde and dihydroxyacetone phosphate;whereas glucose is 
catabolized to the dihydroxyacetonephosphate and glyceraldehyde 3- 
phosphate. This difference may account for the fact that fructose 
is a better precursor of triglycerides than glucose. For example, 
glyceraldehyde may be converted more rapidly to a-glycerophosphate 
than either glycoraldehyde 3-phosphate or dihydroxyacetone, phosphate, a- 
Glycerophosphate, of course, can accept acyl groups from acyl €o A 
derivatives and is hence a major precursor of triglycerides.
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The Sex Hormones and their effect on Carbohydrate 
and Lipid Metabolism
Sex hormones have been found to influence the development of 
atherosclerosis. Estradiol improves the condition by correcting 
abnormal lipid levels. Testosterone on the other hand aggravates 
the disease by being antagonistic towards estrogen and by increasing 
cholesterol levels (114).
Once secreted by endocrine glands the steroid hormones, bound 
to specific hormone-binding proteins, use the blood stream to reach 
their target cells. These hormones penetrate the cells, in contrast 
to the action of certain peptide hormones which act at the level of 
the external membrane. In the cell the hormones act to change certain 
enzyme levels and as a consequence the metabolic pathways of the cell 
will be modified.
4
The activities of enzymes ( ^  -5a-hydrogenase, steroid hydroxy­
lases, 3(z- and 3p-hydroxysteroid dehydrogenase and 20-ketoreductase) 
concerned with the metabolism of both male and female hormones were 
studied in rat liver with respect to their dependence on age and sex 
over a period of 1-180 days after birth (299). A uniformly increasing 
activity, with no difference between the sexes was observed during the 
infant phase (the first 30 days). Sexual differentiation of steroid 
metabolizing enzymes in the rat liver is a process which starts at 
birth (300). The experimental data of Denef and De-Moor (301) shows 
that the potential development of the steroid metabolizing enzymes is b 
basically feminine in the newborn male rat. Testosterone, which appears 
within a few critical days after birth, primes a masculine differentiation. 
The hormone at that moment acts as an organizer so that at the age of 
puberty (30 days), a masculine pattern of metabolism comes to expression 
and is retained at a significant level during the whole lifespan, even 
in the absence of any further source of male sex hormones after 
castration and adrenalectomy.
Schriefer et al (299) similarly report that the infant phase in 
rats is followed by a phase of variable length during which sexual 
differences in metabolism are first apparent (puberty). This is followed 
by the phase in which enzyme activities remain at a sex-specific plateau 
(full sexual maturity). Finally, in the so called ageing phase, there is
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a decrease in A  -5o-hydrogenase activity: levels of other steroid- 
metabolizing enzymes do not, apparently, change during this phase.
The biosynthetic pathways for the biosynthesis of sex hormones 
have been well established and these are summarised in Fig. 3.
Estrogens
The estrogens in combination with other hormones, are 
responsible for the development and maintenance of the female sexual 
organs. Estrogens are produced in the gonads, the placenta and the 
adrenal cortex. The main site of formation in the female is normally 
the ovary, but during pregnancy the quantity synthesised by the 
placenta increases until in late pregnancy this contribution may be a 
thousand times greater than that of the ovary. Of the three main 
estrogens in humans, estradiol-17p is biologically more potent than 
estrone or estriol, as judged by bioassays.
Estrone is produced in a sulphated form by the adrenal cortex 
(302) and this derivative is reduced to estrodiol-17p 3-mono sulphate 
which in turn is hydrolysed by microsomal enzymes to estradiol-17^.
Estrone sulphate is more readily converted to estradiol-17p than is 
estrone itself (303). This is presumably because sulphate groups 
protect estrogens from biological inactivation (304).
The studies of Means and O'Malley (305) indicate that estradiol- 
17p, when it first appears in the uterus, binds to a cytoplasmic 
receptor protein (Fig.4). This complex is then modified in some 
manner and transferred to the nucleus. A stimulation of synthesis of 
nuclear RNA ensues and this leads to enhancement of protein synthesis, 
some of which appears in the cytoplasm, and some in the nucleus. It is 
possible that the induction phase may result in an amplification phase; 
(i.e., increased synthesis of nuclear RNA which in turn is transported 
to the cytoplasm for the overall regulation of uterine protein synthesis).
Estrogen induces a profound oviduct growth in chicks (306), 
primarily by hyperplasia (increased amount of DMA). Progesterone alone 
has little or no effect on oviduct growth, however, in combination with 
estrogen it antagonizes the estrogen-induced hyperplasia of oviduct, 
but synergizes with estrogen in eliciting cellular hypertrophy. In 
gonadectomized rats exposure to a constant physiological dose of labelled
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Pig, 4 The biochemical effects of estrogens 
on rat uterus
estrogen for a few days results in a highly significant increase in 
retention of the label by rat uteri. Progesterone administration 
during final phasesof estrogen treatment greatly reduces the retention 
of the latter in the target tissues (307), These observations are 
consistent with the known synergisms of the two hormones.
The effect of the administration of estrogenic hormones to males 
depends on the dosage of the hormone, the duration of treatment and the 
age and species of animal; the simultaneous administration of androgens 
also influences it. The principal action of estrogens is anti- 
androgenic, i^ they can inhibit and antagonize the effects of androgens 
(308),
Vcrmeulen (309) found that both estrogen treatment and pregnancy 
increases the testosterone binding capacity of testosterone binding 
protein (T.B.G. [globulin]]). He quoted evidence to suggest that T.B.G* 
bound testosterone is biologically less active than free testosterone. 
Indeed, high testosterone plasma levels in pregnancy or during estrogen
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treatment are not accompanied by signs of hyperandrogenism. Moreover 
the metabolic clearance of testosterone decreases when T.B.G. is 
increased.
Vertes and King (310) confirm observations of previous workers 
that androgenization affects the hypothalamus and that it may exert 
its effect by altering the binding of estradiol to receptors in this 
region of the brain. It remains uncertain whether androgenization also 
directly affects estradiol binding in the adenohypophysis and uterus; 
or whether this is a secondary effect governed by the primary reaction 
at the hypothalamus.
Administering estrogen in combination with progesterone enhances 
the activities of phosphofructokinase, aldolase and fructose 1,6- 
diphosphatase in female chicks (311). Furthermore, estrogen treatment 
alone results in a lesser, but significant, response in the case of 
phosphofructokinase and aldolase activities and no change in fructose 
1,6-diphosphatase activity. Progesterone alone has no observable effect 
on any of these enzymes.
Estrogen or progesterone induces significant increases in liver 
glycogen concentration, combinations of the two hormones exhibit a 
synergistic effect (306).
Female rats pretreated with estradiol,on fasting lose their liver 
glycogen at a lower rate than rats pretreated with testosterone.
Fasting rats injected with cortisol were able to accumulate liver 
glycogen at a higher rate when pretreated with estradiol than with 
testosterone propionate. Large doses of estradiol, but not of testo­
sterone, provoke increased accumulation of liver glycogen in fasting 
normal rats, but not in fasting adrenalectomized animals (312). In rat 
uterus, enzymes which occur at branch points of metabolism, viz. 
particulate bound hexokinase, glucose 6-phosphate dehydrogenase and 
ribulose 5-phosphate isoraerase show a five-fold increase in activity 
following estradiol treatment. Of the other enzymes in the glycolytic 
and pentose phosphate pathways the increase in activity after estradiol 
treatment was only two-fold. It is suggested (313) that the large 
increases observed in the above 3 enzymes is in accordance with the 
concept that control occurs at branch points of metabolism (314).
Seng et al (315) report that synthetic estrogens caused slight 
but significant increases in the levels of triglyceride, glyceride-glycerol.
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aceto&cetate and pyruvate in 12 normal young women. No significant 
changes were observed in other lipids.
In male, weanling rats the specific activity of diglyceride 
acyltransferase is decreased by estradiol pretreatment in both 
castrated and normal animals. The activity in castrated animals was 
increased by testosterone (316),
Hence, in conclusion, it is apparent that estrogens can 
regulate protein synthesis and, to some extent, the metabolism of 
carbohydrates and fats.
Androgens
The androgens are synthesised in the Leydlg or interstitial 
cells of the testis under the influence of the gonadotrophins and 
in the adrenal cortex under the influence of corticotrophin. Gonado­
trophin secretion is regulated by androgens in a feed back system 
acting on the hypothalamus (317).
Kniewald et al (318) suggest that the adrenal gland of normal 
male rats is capable of producing testosterone, and that the synthesis 
of this hormone by the adrenals is increased immediately after 
castration. Moreover, the adrenal gland also contributes to the 
biosynthesis of testosterone in an indirect fashion, i_e by providing 
the testis with an essential precursor, possibly progesterone.
The two main pathways for testosterone biosynthesis are shown 
in Fig. 5.
Coffey et al (319) have shown that in vitro the conversion of 
progesterone to testosterone in the testis, a functional capacity 
acquired during fetal life (320) remains intact in animals up to maturity.
In view of the relative potencies of the three androgens, 
testosterone, androstenedione and dehydroepiandrosterone, and the low 
metabolic clearance rate of testosterone as compared with the other 
two hormones, the androgenic activity of adult male plasma is pre­
sumably due mainly to the presence of testosterone (321).
In vitro studies have demonstrated 5o-dihydrotestosterone 
(5aDHT) formation from testosterone in the nuclear fraction of kidneys 
obtained from both male and female rats (322). Recently 5aDHT has 
been found to be more firmly bound than testosterone to nuclear 
chromatin material in androgen target tissues such as prostate (323).
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Fig 5 The main pathways for Testosterone biosynthesis
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It is suggested that 5aDHT may be the active androgen in these tissues, 
and that testosterone is the main transport form in the blood (324).
Unbound testosterone in plasma is more biologically active 
whilst the protein-bound fraction serves as a reservoir and transport 
form of the hormone. The biologically active 170-hydroxysteroids are 
largely bound to a specific p-globulin, which has a high affinity but 
low binding capacity for testosterone, and albumin, which has a low 
affinity but high capacity for testosterone (309,325).
Variations in the proportions of unbound testosterone and 
5aDHT could influence the expression of biological activity. Clarke 
et al (325) observed a significantly lower per cent binding of bfoth 
hormones for normal men than for normal women. The levels were elevated 
in men receiving estrogen, in pregnant women and in women receiving oral 
contraceptives.
Jungblut et al (326) found that female and male secondary sexual 
organs contain cytoplasmic receptors for estradiol and 5aDHT, both 
receptors exhibiting differences in their steroid binding specificity*
3
A 10 -fold excess of estradiol completely inhibits the attachment of
3
5aDHT to the androgen receptor. Competition by a 10 -fold excess of 
5aDHT results in only a 42% reduction of receptor-bound estradiol. It 
is suggested that the deprivation of androgen receptors could suppress 
the growth promoting effect of androgenic hormones.
In addition to the androgenic effects of testosterone, it also 
has powerful metabolic activity and causes retention of nitrogen, 
potassium and phosphorus. It increases body weight particularly by 
growth of bone and muscle, and administration of the hormone is followed 
by a very early increase of nuclear RNA synthesis in the kidney (327). 
Pew specific biochemical effects appear to have been observed with 
androgens.
Progesterone
Progesterone is secreted by the corpus luteum of the ovary and 
is responsible for preparing the endometrium for pregnancy. Its bio­
synthesis in vitro from ^^C-labelled acetate via cholesterol has been 
demonstrated using human corpora lutea (328) (see Fig. 3).
The hormone was observed to have no significant effection lipids 
and lipoproteins (114), however, serum cholesterol, triglycerides and
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phospholipids all rise steadily in pregnancy as the estrogen and 
progestogen output increases (329,330). Recently Stokes and Wynn 
(134) reported that the most progestational oral contraceptive pills 
were associated with the highest cholesterol values in women.
Bolton et al (149) report that contraception by continuous 
administration of a progestogen compound such as chlormadinone is 
not accompanied by changes in the platelet electrophoretic behaviour 
(p.e.b.) (p.e.b. is abnormal in patients with occlusive arterial 
disease) and may, therefore, not be associated with vascular disease.
Prostaglandins
The prostaglandins are a class of C^q fatty acids containing a 
cyclopentane ring. They are unusual among highly active biological 
ccunpounds in that they lack nitrogen in which respect they resemble 
the steroid hormones.
The precursors of prostaglandins are the essential fatty acids 
and in man the biosynthetic pathway is shown in Fig. 6.
There is evidence to suggest that prostaglandins may be involved 
in the genesis and prevention of atherosclerosis and thrombosis (331). 
Kloeze (332) has demonstrated in vitro that platelet adhesion and 
aggregation induced by ADP and by collagen can be prevented or counter­
acted by PGB^. A tentative theory is that PGB^ influences atherosclerosis 
by permeating and/or coating the vessel wall which in turn influences 
the initial thrombus development.
PGE^ can also cause vasodilation and hence decrease the blood 
pressure, a further important factor implicated in atherosclerosis (331).
Vergroesen et al (333) showed that the contractile force of an 
isolated perfused heart is stimulated by prostaglandins F^^ and 
These compounds, which are mainly synthesised in lung tissue, and 
then immediately transported to the heart, could, therefore, also 
influence coronary thrombosis and myocardial infarction.
Maxwell (334) reports that PGB^ and PGF^^, have contrasting 
properties. He noted (334-335) that PGB^ and PGF^^, separately, cause 
considerable cardio-acceleration; given together, however, they have 
relatively little effect on heart rate. The hypotensive effect 
(vasodilation) of PGB^ is not abolished by PGF2^(334), in so far as a 
decrease in systemic pressure is always found when the two fatty acids
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are administered together. PGPg^ increases pulmonary arterial 
pressure (334), whereas PGB^ has little effect (335). The pulmonary 
hypertensive effect of PGPg^ is apparently abolished if PGE^ is given 
concurrently. Similarly, the increase in cardiac output which occurs 
with PGE^ no longer occurs if stoichiometric amounts of PGPg^ are 
given at the same time.
The suggested role of prostaglandins in the development of 
atherosclerosis fits in well with the filtration theory advanced by 
Constantinides (336) concerning the influence of dietary fat on the 
disease. He suggests that a normal diffusion of lipoproteins occurs 
from the lumen into the adventitia across the arterial wall. These 
lipoproteins may be trapped in the intima, causing the development of 
atherosclerosis. This process %#ould be promoted when the blood lipid 
level is increased. In addition, the blood pressure and the permeability 
of the vessel wall is assumed to play a part. Hence the hypotensive 
effect of PGEj and its prevention of platelet aggregation would appear 
to counteract the lipid penetration and retard the development of the 
atherosclerotic process.
R E S U L T S A N D D I S C U S S I O N
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There is a considerable amount of literature concerning 
differences in carbohydrate metabolism in men and women and many 
attempts have been made to link these observations to a theory of 
atherogenesis. Of particular importance is the fact that sucrose 
and fructose, but not glucose or starch, can increase the levels 
of fasting blood serum triglycerides in men and post-menopausal 
women, but not in pre-menopausal women (33,35,36,47). Triglycerides 
are the most abundant lipids in the arterial plaques in coronary 
arteries in the early stages of atherosclerosis (6). Hence there 
could be a relationship between dietary sucrose and heart disease.
An obvious hypothesis is that fructose is a better precursor of 
triglycerides than glucose.
This project was undertaken to examine in greater detail the 
metabolism of fructose in the liver and to investigate possible 
control of the metabolism of this sugar by sex hormones.
Initially it was intended to investigate in detail the con- 
14version of C-fructose to triglycerides in rat liver slices and to 
examine possible sex hormonal control of this complex pathway.
Preliminary experiments were designed to measure the relative 
incorporation of label into the glycerol and fatty acid moieties of 
the triglycerides and to compare the fates of fructose and glucose.
The liver is the major organ for triglyceride synthesis and hence 
liver slices were chosen for this study.
Conversion of fructose to triglycerides
Liver slices from both male and female animals were incubated
14in Lrebs-Ringer Bicarbonate containing either C-(U)-fructose or 
14C-(U)-glucose. Incubation was followed by maceration of the tissues 
and removal of non-saponifiable lipids with 61oor*s Solvent. The 
residual extract was then saponified and resolved into fatty acid and 
glycerol fractions. The radioactivity in the two fractions was deter­
mined by liquid scintillation counting and the percentage incorporation 
of label calculated. The results are summarised in Tables I, II and 
III.
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TABLE f. Incubation of male rat liver slices with C-(U)- 
fructose and ^^C-»(U)-glucose for 1 hr. at 37^C.
14C-(U)-fructose c.p.m./5g. wet wt. liver tissue
Fructose
total
c.p.m.(a)
Residual* 
fructose 
c.p.m.(b)
Glyceride glycerol Fatty acids
Total 
c.p. m.
% incor­
poration /
Total % incor­
poration
570,000 266,000 23,120 9.3 2,100 0.69
^^C-(XI)-glucosc c.p.m./5g. wet wt. liver tissue
Glucose 
total 
c.p.m.(a)
Residual 
glucose 
c.p.m.(b)
Glyceride glycerol Fatty acids
Total 
c.p. m.
% incor­
poration
Total
C.p.m.
% incor­
poration
750,000 325,000 23,180 6.6 1,626 0.38
* Labelled fructose remaining in incubation medium plus 
tissue washings
Total c.p.m. x 100 
Total (a) - Total (b)
%
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TABLE JI- Incubation of male rat liver slices with Ç.(U)-
 ^A Q
fructose and O(u)-glucose for 1 hr. at 37 C
14C-(U)-fructose c.p.m./5g. wet wt. liver tissue
Fructose
total
c.p.m.
Residual
fructose
c.p.m.
Total 
lipids 
c.p.m.
Free
glycerol
Glyceride
glycerol Fatty acids
Total 
c.p .m«
% Incor­
poration
Total 
c.p. m<
% incor­
poration
Total
c.p.m
% incor­
poration
760,000 208,500 21,000 34,00C 6.2 8,400 1.5 560 0.1
^^C-(U)-glucose c.p.m./5g. wet wt. liver tissue
Glucose 
total 
c.p. m.
Residua: 
glucose 
c.p « m.
Total 
lipids 
c.p. m.
Free
glycerol
Glyceride
glycerol Fatty acids
Total 
c.p. m«
% incor­
poration
Total 
c.p. m«
% incor­
poration
Total
G.p.m«
% incor­
poration
760,000 387,000 13,080 19,00C 4.9 4,200 1.1 410 0.1
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14TABLE Hi* Incubation of female rat liver slices with C-(U)-
' 14 ' ' ' Q
fructose and C-(U)-glucose for 1 hr. at 37 C
14C-(U)-fructose c.p.m./5g. wet wt. liver tissue
Fructose 
total 
c.p.IB.
Residual
fructose
c.p . XB.
Total
lipid
C#p* ûfl
Glyceride Glycerol Fatty acids
Total
c.p .5. % incor­poration
Total
c.p.m.
% incor­
poration
760,000 445,450 28,703 17,200 5.3 1,020 0.31
14C-(u)-glucose c.p.m./5g. wet wt. liver tissue
Glucose
total
c.p.m.
Residual
glucose
c.p.m.
Total 
lipid 
c.p. m.
Glyceride glycerol Fatty acids
Total
c.p.m.
% incor­
poration
Total
c.p.m.
% incor­
poration
760,000 594,240 13,800 6,100 3.7 1,200 0.72
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It is clear from these experiments, that In all tissues both 
glucose and fructose give rise to a greater incorporation into tri- 
glyceride glycerol than fatty acid. Fructose, however, -is a better 
source of label than glucose in both fat components. With male liver 
tissues the glycerol/fatty acid activity ratio is approximately the 
same with incorporation from both hexoses into glycerol being 10-17
times greater than into the triglyceride fatty acid. The same is
tri 
14,
ue with female tissues incubated with ^^C-fructose, however with
C-glucose the activity ratio is significantly decreased to 5s1.
There appears to be a greater incorporation of label into the 
triglyceride fraction of the total lipids in male liver tissues when 
fructose is incubated in comparison with glucose (43 and 33%, 
respectively). A similar differential occurs with female liver tissues
(65 and 52%). u
q
This present study^confirm previous suggestions that trigly­
ceride may be produced more readily from fructose than glucose (69,96, 
97,108). This approach to the problem of fructose/triglyceride 
relationships was, however, discontinued in view of the difficulties 
of experiment interpretation which were likely to be encountered 
because of differences in the tissue pool sizes of glucose and fructose 
and their derivatives.
^Instead it was decided to direct the investigation towards the 
individual enzymes likely to be involved in the conversion of fructose 
to triglyceride and to examine the possible sex hormone effect on the 
individual stages in this pathway (see Fig. 7).
Hormonal control of Fructose phosphorylation (fructokinase
activity)
Initial experiments were designed to measure the rates of fructose 
utilisation in both male and female animals and to investigate whether 
these enzymes, and in particular fructokinase, were subject to control 
by estrogens and androgens.
The site of fructose phosphorylation in liver cells was first 
checked. A combination of differential and zonal centrifugation was 
used (as outlined in the scheme (Fig.8)) tofractionate the cell 
contents.
6 6
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Fig. 7. Pathways involved in fructose metabolism
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Homogenate in 0.25M sucrose -
0.Û5M Sodium CaCodylate (pH é.5)
Centrifuge for
10 min. at 650g.
Nuclear
fraction
:
Supernatant
t--------------
Supernatant
Centrifuge for
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10 min at 22,50ûg,
%
lysosomes and 
mitochondria
30 min. at 
I00,000g.
zonal centrifugation
r I in linear
Soluble microsomal 17-55%
supernatant fraction sucrose gradient
i I
lysosomes mitochondria
Fig. 8. Fractionation of liver cells
(see Schneider and Hogeboom (337), 
Brown and Brown (338))
The rate of phosphorylation of fructose by each fraction was 
measured by incubation with ^^C-fructose, F*ions and ATP and separating 
the resulting fructose phosphates by paper chromatography. Radioactivity 
was then measured by a scintillation technique.
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TABLE IV. Fructose phosphorylation by liver cell fractions 
from a male rat
Liver wt. *» 12.Og.
Fraction Volume
ml.
Protein
mg/ml.
Activity*
/ml.
Specific / 
Activity
Total
Activity
(X 10-*)
Nuclear 13.3 16.0 602,500 505 8.03
Mitochondrial 6.3 3.5 58,000 122 0.37
Lysosomal 3.6 - - - -
Microsomal 7.0 4.0 394,000 1,310 2.76
Soluble
supernatant
52.0 11.75 1,400,000 1,570 72.3
TABLE V. Fructose phosphorylation by liver cell fractions 
from a female rat
Liver wt. » 6.9g.
Fraction Volume
ml.
Protein
mg/ml.
Activity*
/ml.
Specific / 
Activity
Total
Activity
(X 10-*)
Nuclear 14.5 4.25 236,000 738 3.43
Mitochondrial 5.0 - -
Lysosomal 4.2 0.2 - - ~
Microsomal 6.8 0.2 105,700 7,040 0.72
Soluble
supernatant
28 5.25 791,000 2,000 22.2
* c.p.m. fructose phosphate/ml.
/ c.p.m. fructose phosphate/mg. sol. protein/min.
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As can be seen in Tables IV and V the soluble supernatant 
fraction from both male and female livers possesses most of the 
fructose phosphorylating activity. This confirms previous studies 
(259,339). The small amount of activity occuring in the other 
fractions is probably due to contamination by the soluble enzyme.
In all the studies which followed the soluble supernatant 
solution was used as a source of enzyme and was prepared by centri­
fugation of homogenates first at 5000g. to remove gross cellular 
debris, and then at 100,000g. to sediment organelles.
The identity of the phosphate produced by incubation of ^*C- 
fructose with ATP and the supernatant fraction was examined by paper 
chromatography. Fructose 1-phosphate was the only hexose derivative 
which could be detected. This observation was confirmed by treating 
the enzyme preparation with acid (to pH 6.0) and then examining the 
rate of fructose phosphorylation in the presence of 2-acetamido-2- 
deoxy-D-glucose. Acid treatment destroys much of the hexokinase 
(but not fructokinase) activity and the remainder is inhibited by 
the amino sugar derivative (259).
TABLE VI. Fructose phosphorylation by acid treated enzyme
preparations in the presence of 2-acetamido-2-deoxy- 
D-glucose.
No* Sex Incubation 
Time (min.)
Untreated enzyme 
preparation (Total 
(cip.m.) X 10~G
Treated enzyme 
(Total c.p.m.) 
X 10-&
30 2.17 2.19
I Male 60 3.50 3.43
60 3.41 3.46
2 Male
30 0.37 0.33
60 0.60 0.62
30 0.34 0.35
3 Female
60 0.68 0.68
* Different radioactive concentrations were used in the three experiments
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In this instance the phosphorylation rates using treated 
and untreated enzyme were almost identical (see Table VI) thus 
showing that fructokinase is the major phosphorylating enzyme in 
the liver preparations.
Although fructose 1-phosphate was observed to be the major 
product some triose phosphates (see P. 97) were also apparent when 
enzyme digests were examined on paper chromatograms. The radio­
activity in these materials was only 5-10% of that present in the 
fructose 1-phosphate. In calculating rates of fructose phosphory­
lation the total counts in the fructose 1-phosphate and triose 
phosphates were used, however.
Having established that fructose was converted mainly to 
fructose 1-phosphate by liver tissue extracts the rate of fructose 
phosphorylation was measured in animals over a range of ages. The 
results expressed in pinoles fructose phosphorylated/min./mg. soluble 
protein or per total wt. liver tissue are shown in Figs. 9 and 10.
Walker (103) examined hepatic fructokinase in new-born 
guinea pigs liver and basing his results in terms of pmoles fructose 
utilised/min./g. wet wt. liver tissue (or lOOg. body wt.) found that 
fructokinase activity appeared after birth and reached adult levels in 
7-10 days.
Three day old rats exhibited a high fructokinase specific 
activity which fell sharply at 10 days. As the total activity per 
liver rose during this period (Fig. 10) the decrease in specific 
activity was presumably due to protein: synthesis. After 10 days there 
was a more gradual decrease in fructokinase activity over a period of 
4 weeks. At 3^ weeks female rats appeared to have a higher activity 
than the corresponding males from the same litter, although only two 
animals of each sex at this age were available for study. The difference 
in fructokinase activity between the sexes was not apparent at 5^ weeks, 
however in females the activity at 9 weeks was half that observed in 
males at 11 weeks. This latter value was only slightly lower than the 
value observed for 5% week old animals. Enzyme activity continued to 
fall in both sexes after 11 weeks, but was less marked in the case of 
the female animals, however. At about 17 weeks the rate of fructose 
phosphorylation was approximately the same in both sexes.
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The difference in fructokinase activity in sexually mature 
animals is shown in Fig* 11 for males at 11 weeks and females at 
9 weeks* Here it is quite clearly seen that the enzyme activity 
of the livers of male animals is twice that of female animals* 
Hence the effect of sex hormones was next investigated.
Effect of testosterone on fructokinase in female rats 
In initial experiments injection of different doses of 
testosterone in a saline/propylene glycol mixture (3mg. and 24rag./ 
Kg. body weight[kg*b,wt^] were investigated. The results are shown 
in Table VII.
TABLE VII Fructose Phosphorylation in female rats injected
with testosterone (T)
fructose 1-phosphate c.p.m, x 10**^  /rag. sol. protein
^^^Cpn^entr-
Controls 3mg.T/Kg.body wt. 24mg.TAg.body wt.
12 hr. 139,4^4.0
♦ ** 
160.2-4.7 190*1-11.9 ***
48 hr. 136*4-8.7 140.6^5,3 ^
15 min, incubations. Arithmetical means plus standard 
deviations calculated using triplicate samples from 6 livers 
for each assay. Controls were injected with saline/propylene 
glycol, with the hormones for injection dissolved in this 
mixture.
Statistically significant (**P ^  0.01; <C 0.005)
increase in fructokinase activity conçared with control
t  Not significantly different from control.
Twelve hours after a single injection of 3rag./Kg,b,wt, there 
was a 14% increase in activity which fell to the control level 48 hr* 
after injection. In the case of the larger dose there was a more 
marked rise (36%) after 12 hr* but again the level of activity fell 
after 43 hr. Both increases in activity after 12 hr. were significant.
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Fig. 11. Fructokinase in adult male and female rats
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Duplicate assays on livers from 6 animals were carried 
out. lienee each experimental point represents the mean of 12 deter­
minations.
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Fig* 12 shows the results of more detailed experiments where 
rate/time curves have been constructed for injections of single and 
double doses of testosterone into female animals. It can be seen 
that 24 hr. after a single injection (24 mg./Kg.b.wt.) of hormone 
the rate of phosphorylation approximately doubles in comparison with 
the female control and reaches the level of activity in livers from 
normal male animals. A second injection of hormone followed by a 
further 24 hr. period increased the fructokinase activity beyond 
that of the male control.
It is clear from these experiments that male hormone adminis­
tered to female animals increases the rate of fructose phosphorylation 
in vivo. The level of hormone used in these experiments was high, 
but it is probable that only part of that injected was biologically 
active as solid residues were observed, when the animals were sacri­
ficed, at the sites of injection in the sub-cutaneous tissues.
In the Introductory Section the role of sex hormones in promotion 
of protein synthesis was described and in view of the known facts it 
seemed probably that testosterone was affecting fructokinase activity 
by influencing the synthesis of liver proteins. Hence, in vitro 
experiments using liver slices were designed as a first stage in 
testing this hypothesis.
TABLE VIII Effect of testosterone (T) on fructose phosphorylation
in female rat liver slices
p moles fructose utilised/g.wet wt* liver tissue*
Controls 1 mg.T./lOml. K.R. *
0.28-0.016 0.41-0.035**
For each assay, 6 tubes each containing 2 liver slices were used. 
Incubation with hormone or Krebs-Ringer bicarbonate solution was carried 
out for 2 hr. at 37°C. The rates of fructose phosphorylation were then 
measured with duplicate samples from each tube after incubation for 15 min.
* The arithmetical means plus standard deviations were calculated.
+ Weight of testosterone/10 ml. Krebs-Ringer bicarbonate solution.
** statistically significant (P<0.01) increase in fructokinase activity 
compared with control.
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Fig. 12. Fructokinase in female rats injected with testosterone.
(T = male rats injected with saline/propylene glycol and sacrificed 
after 24 hr.
= female rats injected with saline/propylene glycol and sacrificed 
after 24 hr.
? + 1 T = female rats injected with testosterone (24 mg./Kg.b.wt.) in 
saline/propylene glycol and sacrificed after 24 hr.
? + 2 T = female rats injected twice with testosterone (24 mg./Kg.b.wt.)
in saline/propylene glycol; the second injection given 24 hr. 
after the f i rs t  and the animals sacrificed after a further 24 hr,
Duplicate assays on livers from 6 rats were carried out; therefore 
each experimental point represents the mean of 12 determinations.
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TABLE IX Effect of testosterone (T) on fructose phosphory- 
lation in female rat liver slices
^^C-fructose 1-phosphate formation (c.p.m. x loT^) 
/mg. soluble* protein
Control 0.63 mg.T/10 ml. K.R. ^
1893.4^1.11 ** 2552.6^22.8
♦ For each assay, 6 tubes each containing 2 liver slices were used. 
Incubation with hormone or Krebs-Ringer Bicarbonate solution was 
carried out for 3 hr. at 37^C. The rates of fructose phosphory­
lation were then measured with duplicate samples from each tube 
after incubation for 15 min. The arithmetical means plus 
standard deviations were calculated.
4^  Weight of testosterone/10 ml. Krebs-Ringer bicarbonate solution.
Statistically significant (P<p.025) increase in fructokinase 
activity compared with control.
Table VIII shows that incubation of liver slices with testo­
sterone produces a statistically significant elevation of fructokinase 
activity. In this series of experiments the enzyme activity was assayed 
by measuring loss of fructose from the medium using a resorcinol/thiourea
reagent. The investigation was repeated using the routine procedure 
14with C-fructose as substrate and assaying the labelled phosphate 
formed; again (Table IX) it was obvious that the male hormone signifi­
cantly activated the kinase in the female liver tissues.
Further studies including the use of varying concentrations of 
testosterone and varying incubation times from 1-12 hr. were made. In 
all cases activation was observed although there was a poor correlation 
between enzyme activity and the varying factors.
The wide spread in the results obtained from the in vitro studies 
are probably due to permeability differences, ie. uneven thickness of 
tissue slices.
Effect of testosterone on fructokinase in male rats 
The experiments carried out with female rats were repeated with 
male animals.
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TABLE X Fructose phosphorylation in male rats injected
with testosterone (T)
14C-fructose 1-phosphate formation (c.p.m. x 
10*^)/mg* soluble* protein
Time Control 24mg.T/Kg.b.wt.
24h m.elô.ô ** 152.0-5.2
4Sh *** 130,3^4.9
72h ^  129.9-7.0
* 15 min. incubations. Arithmetical means plus 
standard deviations calculated using triplicate 
samples from 6 livers for each assay. Controls 
were Injected with saline/propylene glycol, with 
the hormones for injection dissolved in this 
mixture.
** Statistically significant (** P < 0.005; *** 
P 0.05) increase in fructokinase activity 
compared with control.
^ Not significantly different from control.
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TABLE XI Fructose phosphorylation in male rats injected
with testosterone (T)
^^C-fructose 1-phosphate formation (c.p.m. x 10"^)/mg. 
soluble protein *
^ C ^ c e n t r a -
Controls
3rag.T/Kg.
b.wt.
12mg.TAg.
b.wt.
24mg.T/Kg.
b.wt.
12h 182.9-8.7
**
2 2 5 .7 -8 .6
***
2 5 6 .1 -1 0 ,2
****
214.8^7.1
43h 19 5 .5 -11 .3 195 .8 -14 .9 1 7 8 .7 -7 .5
* 15 min. incubations. Arithmetical means plus standard deviations
calculated using triplicate samples from 6 livers for each assay. 
Controls were injected with saline/propylene glycol, with the 
hormones for injection dissolved in this mixture.
** Statistically significant (**?<. 0.01; *** P < 0.001;
**♦* P < 0.025) increase in fructokinase activity compared****
with control, 
f Not significantly different from control.
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TABLE XII Fructose phosphorylation in male rats injected with
testosterone (T)
14 «.3 C-fructose 1-phosphate formation (c.p.m. x 10 )
*
/mg. soluble protein
Cone en- 
^^^^Mtion 
Time(hr. )
Controls 12mg. T./Xg.b.wt.
1 102.3-2.5
** +
87.6-0.9
3 100.7-2.9
6 *** 123.0-1.8
12 ^*118.3^1.8
15 min. incubations. Arithmetical means plus 
standard deviations calculated using triplicate 
samples from 6 livers for each assay. Controls 
were injected with saline/propylene glycol, with 
the hormones for injection dissolved in this 
mixture.
Statistically significant (P <  0.01) decrease 
in fructokinase activity compared with control.
t Not significantly different from control.
Statistically significant 0.001;
0.001) increase in fructokinase activity 
compared with control*
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The résulta shown in Tables X - XII and Fig. 13 are all 
statistically significant and indicate that as with female animals, 
testosterone increases the fructokinase activity in male liver 
tissues. The optimum dose appeared to be 12 mg./Kg.b.wt. with a 
period after injection of from 6 to 12 hr. and the effect was 
greatest (Fig.13) when two injections of testosterone (24 mg./Kg. 
b.wt.) were given.
An in vitro investigation (Tables XIII and XIV using liver 
slices from male rats showed that testosterone was also able to 
increase the specific activity of the fructokinase in the male tissues.
In Table XIV where the results are based on g.wet wt. liver 
the decrease in specific activity in the controls is due to the 
gradual disintegration of the slices. However in the 3hr. incuba­
tions the level of fructokinase induced by the testosterone is signi­
ficantly different from that in the control.
In order to investigate the probable involvement of protein 
synthesis in testosterone-treated slices the e:)q)eriments were repeated 
in the presence and absence of cycloheximide (Table XV). Statistical 
treatment of these results shows that the increase actually produced 
by testosterone is nullified by the presence of cycloheximide. It may 
be assumed, therefore, that the hormone functions by activating fructo­
kinase synthesis in male and presumably female tissues. A second but 
less likely possibility is that the synthesis of another protein 
(enzymic or non-enzymic) is enhanced which in turn activates the kinase. 
Such systems being well known, to take one example, in glycogen 
metabolism.
Effect of estrone on fructokinase in male rats 
In view of the observed activation of fructokinase by testo­
sterone the effect of estrone on the enzyme was next investigated. 
Injections of estrone (24mg/Kg.b.wt.) into male rats produced no effect 
after 24hr.,however,a second injection 24hr. after the first produced 
a change in the kinetics of the enzyme after a further 24hr. The results 
are shown in Fig.14 and these have been confirmed by a repeat experiment. 
It can be seen that the initial rate of activity is normal up to 15 min. 
incubation, however after this period there is a sudden reduction of 
rate. This change in the gradient of the curve cannot be attributed to
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= male rats injected with saline/propylene glycol and sacrificed 
 ^ after 24 hr.
(? + IT = male rats injected with testosterone (24mgcAg.b.wt. ) in 
saline/propylene glycol and sacrificed after 24 hr.
f? + 2T = male rats injected twice with testosterone (24ng./Kg.b.wt.) 
in saline/propylene glycol; the second injection given 24hr. 
after the f i rs t  and tlie animals sacrificed after a further 24 hr.
Duplicate assays on livers from o rats were carried out; therefore 
each experimental point represents the mean of 12 determinations.
Fig. 13. Fructokinase in male rats injected with Testosterone
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TABLB XIII Fructose phosphorylation in male rat liver slices
incubated with testosterone (T)
14 -3 C-fructose 1-phosphate (c.p.m. x 10 )/
g.wet wt. liver tissues *
Control 6 hr. 83.4^6.5
**
12rag.T. 6 hr.
***
125.2-10.7
Control 12 hr. 29.4I 4.2
**
12mg. T. 12 hr.
t + 
27.2- 1.1
* For each assay 6 tubes each containing 2 liver 
slices were used. Incubation with hormone or 
Krebs-Ringer Bicarbonate was carried out for 
6 and 12 hr. at 37^. The rates of fructose 
phosphorylation were then measured with duplicate 
samples from each tube after incubation for 15 min. 
Arithmetical means plus standard deviations were 
calculated.
Weight of testosterone/IOml. Krebs-Ringer 
Bicarbonate solution.
*** Statistically significant (P <  0.025) increase in 
fructokinase activity compared with control.
t Not significantly different from control.
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TABLE XIV Fructose phosphorylation in male rat liver slices
incubated with testosterone (T)
^^C-fructose 1-phosphate (^^C-F-1-P)
c.p.m. X 10*^
Sample 14C-F-1-P_^ 
wt.liver tissue
14
CrF-1-P^
^^mg^sol.*
protein
Controls Ohr. 48.1Î2.9 166.7-7.8
Controls 3hr. 16.4—0.4 160.8^7.1
t
0.63mg.T 3hr.
**
23.8Î2.3
**-*
223.6-15.6
For each assay 6 tubes each containing 2 liver 
slices were used. Incubation with hormone or 
Krebs-Ringer Bicarbonate was carried out for 3 hr. 
at 37^. The rates of fructose phosphorylation 
were then measured with duplicate samples from 
each tube after incubation for 15 min. Arithmetical 
means plus standard deviations were calculated.
t Weight of testosterone/IOml. Krebs-Ringer Bicarbonate 
solution.
*** Statistically significant (**p < o.OI; < 0.005)
increase in fructokinase activity compared with 
respective 3hr. controls.
85
TABLB XV Fructose phosphorylation in male rat liver slices incubated
with testosterone (T) and cycloheximide (C)
C-fructose 1-phosphate (F-1-P) c.p.m. x 10*
Sample P-1-P/g.wet.wt* 
liver tissue
*
F-1-P/mg. soluble 
protein
Control Ohr. 614.0-43.3 1874.0-99.0
Control 3hr. 245.6^27.3 1887.8-42.1
*0.5mg.T 3hr.
**
744.1-112.8 5317.6Î677.2
^0.5mg.T; 4mî4C 3hr.
***
375.8-109.7
+ + 
2843.6-810.0
*• For each assay 6 tubes each containing 2 liver slices 
were used. Incubation with hormone or Krebs-Ringer 
Bicarbonate was carried out for 3 hr. at 37°. The rates 
of fructose phosphorylation were then measured with 
triplicate samples from each tube after incubation for 
15 min. Arithmetical means plus standard deviations were 
calculated.
X Weight of testosterone/IOml. Krebs-Ringer Bicarbonate 
solution.
♦♦ Statistically significant (P <  0.006) increase in 
fructokinase activity compared with 3 hr. control.
*** statistically significant (P <  0.05) decrease in fructo- 
kinase activity compared with testosterone incubation.
(ii)Not significantly different from 3hr. control.
t Statistically significant (P <  0.001) increase in fructo­
kinase activity con^ared with 3hr. control.
+• Statistically significant (P <0.05) decrease dn fructo- 
kinase activity compared with testosterone incubation.
(ii)Not significantly different from 3hr. control.
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Pructokiiiase in male rats injected with Estrone
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# + 2E
= ieniaie rats injected with saline/propylene glycol and sacrificed 
after 24hr.
= male rats injected with saline/propylene glycol and sacrificed 
after 241ir.
(? + IE = male rats injected with estrone (24mg./Kg.b.wt. )  in saline/ 
propylene glycol and sacrificed after 24hr.
(? + 2E = male rats injected twice with estrone (24mg./Kg.b.wt.) in
saline/propylene glycol; the second injection given 24hr. after 
the f i r s t  and the animals sacrificed after a further 24hr.
Duplicate assays on livers from 6 rats were carried out; 
therefore each experimental point represents the mean of 12 determinations,
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depiction of substrate. Instead it suggests that the hormone in some 
way affects the stability of the kinase perhaps by interfering with 
the synthesis of some stabilising factor, possibly a nonenzymic 
protein. Alternatively, estrone may prevent the synthesis of an 
enzyme which activates fructokinase, or the hormone may enhance the 
synthesis of an enzyme which in some way lowers the activity of the 
kinase. A fourth possibility is that the hormone promotes the 
synthesis of an enzyme which destroys the product fructose 1*phosphate. 
In theory this could be a phosphatase which renders the reaction 
reversible. This seems unlikely, however, as a relatively high con­
centration of fluoride ions was added when the fructokinase was assayed, 
When liver slices were incubated at 37^ in Krebs-Ringer bicar­
bonate to which varying concentrations of estrone had been added; a 
reduction of the level of fructokinase was observed, (Table XVI)
A concentration of Img.cstrone/IOmA. Krebs-Ringer bicarbonate 
produced the maximum effect. Levels resulting from treatment with 
higher concentrations were not significantly different.
The effect of incubation/time was also examined with the male 
rat liver slices using estrone (Img./IOml.). Table XVII shows that 
the hormone effect is not apparent after Ihr.
Hence in male animals studies both in vivo and in vitro indicate 
that estrone has an inhibitory effect on fructose phosphorylation in 
the liver.
Effect of^estrone on fructokinase in female rats
The one remaining question which arose as a result of the 
observations already described was whether estrogens exerted the same 
effect in female animals as they did in male animals
The effect of injections of estrone into female animals on 
fructose phosphorylation is shown in Fig.15. Injection of the natural 
female hormone increased the rate of fructose phosphorylation by the 
livers of these animals over and above that produced by testosterone 
(see Fig. 12).
Confirmation of this observed estrone effect was again obtained 
by incubating liver slices from female animals with the female hormone. 
The results of these studies are given in Table XVIII.
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TABLB XVI Fructose phosphorylation in male rat liver slices
incubated with estrone (E)
pM Fructose utilised / g.wet wt. liver tissue*
Control 0.214*0.011
* Img.E
** +
0.141-0.008
Rmg.B
*** +
0.163-0.013
4rag,E 0.157-0.010
8mg.£ ^ 0.143-0.021
For each assay 6 tubes each containing 2 liver 
slices were used. Incubation with hormone or 
Krebs-Ringer bicarbonate was carried out for 2hr. 
at 37*. The rates of fructose phosphorylation 
were then measured with duplicate samples from 
each tube after incubation for 15 min. Arithmetical 
means plus standard deviations were calculated»
X Weight of estrone/IOml. Krebs-Ringer bicarbonate 
solution.
* *
Statistically significant (P < 0.001) decrease in 
fructokinase activity compared with control.
(i) statistically significant (P ^  0.025) decrease in 
fructokinase activity compared with control.
(ii) not significantly different from Img.E.
t Statistically significant ('*'P <  0.005; ^P <  0.025)
/ decrease in fructokinase activity compared with control,
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TABLE XVII Fructose phosphorylation in male rat liver slices
Incubated with estrone (E)
pM Fructose utilised / g. wet wt. liver tissue*
Control Img.E*-
Incubation for 1 hr.
0.156-0.014 * 0.138-0.01
Control Img.E -
Incubation for 2 hr.
0.151-0.024
** 0.094-0.012
For each assay 6 tubes each containing 2 liver 
slices were used. Incubation with hormone or 
Krebs-Ringer bicarbonate was carried out for 
1 or 2 hr. at 37*. The rates of fructose 
phosphorylation were then measured with duplicate 
samples from each tube after incubation for 15 min. 
Arithmetical means plus standard deviations were 
calculated.
Weight of estrone/IOml. Krebs-Ringer bicarbonate 
solution
Not significantly different from control
0,1 > P >  0.05 with P —  0.055 and therefore assumed 
to be a statistically significant decrease in 
fructokinase activity compared with the 2hr. control.
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Fig. 15 Fructokinase in female rats injected with Estrone
phosphorylated 
/mg. sol. 
protein
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- female rats injected with saline/propylene gJyrol 
and sacrificed after 24 hr.
Y + IE = female rats injected with estrone (24mg./Kg.b.wt.)
in saline/propylene glycol and sacrificed after 
24 hr.
? + 2E = female rats injected twice with estrone (24mg./
Kg.b.wt.) in saline/propylene glycol; the second 
injection given 24 hr. after the first and the 
animals sacrificed after a further 24 hr.
Duplicate assays on livers from 6 rats were carried out; 
therefore each experimental point represents the mean of 12 determinations.
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TABLB XVIII Fructose phosphorylation in female rat liver slices
Incubated with estrone (E)
pM Fructose utilised / g. wet wt. liver tissue*
Control 0.118^0.011
^ Img.E
** +
0.234-0.025
4mg.E
+
0.176-0.009
For each assay 6 tubes each containing 2 liver 
slices were used. Incubation with hormone or 
Krebs-Ringer bicarbonate was carried out for 
2 hr. at 37^. The rates of fructose phosphory­
lation were then measured with duplicate samples 
from each tube after incubation for 15 min. 
Arithmetical means plus standard deviations were 
calculated.
Weight of estrone/IOml. Krebs-Ringer bicarbonate 
solution.
Statistically significant (**P <  0.005; 0.005)
increase in fructokinase activity compared with 
control.
Not significantly different from Img.E.
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These observations were unexpected and complicate the over 
simplified view that male hormones are responsible for increased 
triglyceride synthesis from fructose and female hormones responsible 
for a lower triglyceride synthesis from the ketose*
Estrone has been reported to have effects on metabolism which 
may relate to our observations in the case of female rats. For 
example, estrogen administered to fowls, or high levels of endogenous 
estrogen during egg formation, leads to a striking llpemia (340).
It has also been suggested that the synthetic estrogens may be 
responsible for elevated triglyceride levels in pre-menopausal women 
(134,341). The so-called atherogenic index of women using oral contr- 
ceptives approaches that of men of comparable age (130), and the 
incidence of myocardial infarction (114) and of cerebral vascular 
accidents (342) is significantly increased as compared to pre­
menopausal women not using these steroids. Kekki and Kikkila (341) 
suggest that the increased synthesis of plasma triglycerides in pre­
menopausal women might be attributed to the estrogen moiety of the 
•pill*. Stokes and Wynn (134) give confirmation of this in their 
findings that the most estrogenic oral contraceptive pills produced 
high triglyceride levels and the most progestational gave the highest 
cholesterol values. Kekki and Kikkila (341) observed that the rate 
of production of plasma triglycerides increased with the length of 
the treatment period up to 4 yr., while the rate of elimination was not 
related to the duration of contraceptive use. Compatible with this was 
the finding that the over production of plasma triglycerides was reversed 
only slowly after discontinuation of the therapy. Clearly the important 
relationship in female animals between estrogens and high triglyceride 
levels could operate, at least in part, through the metabolism of 
fructose. This would be in line with our original working hypothesis 
that facile triglyceride synthesis from fructose occurs via glyceraldehyde 
and that the rate of fructose phosphorylation is important for regulation 
of this process.
Hormonal Control of fructose 1-phosphate aldolase activity.
This enzyme catalyses the cleavage of the product of fructose 
phosphorylation, fructose 1-phosphate, with the production of dihydroxy- 
acetone phosphate and glyceraldehyde.
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For these studies radioactive fructose 1-phosphate was 
prepared by incubating the 100,000g supernatant of a rat liver 
homogenate with ^^C-fructose. The ^^C-fructose 1-phosphate was 
Isolated by preparative paper chromatography and checked for purity 
by chromatographic methods.
Fructose 1-phosphate aldolase activity was determined by 
incubation of enzyme preparations with the labelled fructose 1- 
phosphate in the presence of fluoride ions. This was followed by 
chromatographic separation of the products (more than 80% of which 
appeared to be triose derivatives) and the residual substrate and 
measuring radioactivities by a liquid scintillation technique. The 
radioactivity of all the products was taken as a measure of the 
aldolase activity. No fructose was produced in these reactions.
In all cases the loss of fructose 1-phosphate corresponded approxi­
mately to the appearance of products; 90-95% of the radioactivity 
could be accounted for.
In preliminary experiments the level of aldolase in liver 
tissues from adult male and female rats (10 weeks old) was measured.
Fig. 16 clearly shows that the activity of the aldolase in the male 
tissues is approximately double that in the female liver. When 
female rats were given a single '-subcutaneous injection of testo­
sterone (12mg,/Kg.b.wt.) and left for 12hr. before preparation of the 
liver enzyme no significant change in aldolase activity occurred (Fig. 
17). In the case of male animals treated similarly with testosterone 
(Fig. 18) there appeared to be a reduction in activity;although the 
exact significance of the results are in doubt because of unexplainable 
variability of the readings obtained, particularly during the later 
stages of the incubations.
Obviously further experimentation with varying hormone doses 
and 'exposure* times are required but it is of interest to note that 
tkc normal levels of aldolase in male and female animals appeartto facilitate 
fructose metabolism in the former. It should be remembered that a 
similar observation was made in the case of fructokinase activity in 
animals of the same age. One would assume that the different aldolase 
levels in males and females are a result of sex-hormone activities, on 
the other hand hormonal control normally relates to enzymes catalysing 
irreversible reactions (343).
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- male rats injected with saline/propylene glycol 
and sacrificed after 12 hr.
= female rats injected with saline/propylene 
glycol and sacrificed after 12 hr.
Duplicate assays on livers from 6 rats were carried out; 
therefore each experimental point represents the mean of 
12 determinations.
Fig. 1(3. Fructose 1-phosphate aldolase in male and female rats.
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'4^  = female rats injected with saline/propylenc glycol
and sacrificed after 12 hr.
? + T = female rats injected with testosterone (12 rag./ 
Kg.b.wt.) in saline/propylene glycol and 
sacrificed after 12 hr.
Duplicate assays on livers from 6 rats were carried out; 
therefore each experimental point represents the mean of 
12 determinations.
Fig. 17. Fructose 1-phosphate aldolase in female rats injected with
testosterone
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Time (mill.)
J = male rats injected with saline/propylene glycol and 
sacrificed after 12 hr.
 ^ + T = male rats injected with testosterone (12mg./Kg.b.wt.)
in sa Line/propylene glycol and sacrificed after 12 hr
Duplicate assays on livers from 6 rats were carried out; 
therefore each experimental point represents the mean of 
12 do te rmi lia t i( uis.
r 1 g. 18. fructose 1-phosphate aldolase in male rats injected with
testosterone
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It was mentioned that small amounts of labelled compounds 
other than the expected products of fructokinase and aldolase 
activities were produced during the assay of these enzymes.
Further experiments were therefore designed to determine the 
nature and levels of these minor components and their relationships 
to the products of fructokinase and aldolase action.
The identity of these various products produced by Incubating 
14high specific activity C-fructose and ATP with liver preparations 
was investigated. This was achieved by paper chromatography using 
P different solvent systems and by paper electrophoresis. In this 
way it was shown (Fig. 19) that the enzyme preparations converted fructose 
to fructose 1-phosphate, dihydroxyacetone phosphate, a-glycerophosphate 
and fructose 1,6-diphosphate. Qualitatively, there was no difference 
with the preparations obtained from male and female animals. A compound 
which behaved as p-glycerophosphate in all the analytical systems was 
also observed although its identity is in some doubt as this compound 
has not been reported before as a metabolite.
The conversion of fructose to hexose phosphates and trioses was 
also investigated qualitatively. In initial experiments fructose at 
two concentrations and two activities was incubated with ATP liver 
preparations from male and female rats of different ages. The results 
of this study are summarized in Table XIX.
Considering the percentage incorporations of label into the 
products from fructose in the younger (12-13 wk.) animal preparations 
it is again clear that fructose phosphorylation activity in the male 
tissues is significantly greater than that in the female. This is also 
accompanied by an increase in trioses in the case of the male. In 
addition, there is probably a greater amount of fructose 1,6-diphosphate 
produced by the female enzyme preparation. It is possible to speculate 
that the larger proportion of fructose 1,6-diphosphate and smaller amounts 
of trioses produced by the female preparation is due to some rate limit­
ing factor in the pathway to a-glycerophosphate and/or triglyceride.
(In this connection it is interesting to note that Dr. A. Fathipour 
in this laboratory (unpublished) has observed that glycerol kinase 
activity is higher in male liver tissues than in female), (see Fig.20).
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Fig. 19. Identification of the Products of C-fructose metabolism
by liver extracts
Paper chromatography (ethylacetate/acetic acid/ formic acid/
water; 18:3:1:4, v/v)
Standards
Labelled fructose metabolites
Paper chromatography ( nethoxy ethanol/methyl ethyl ketone/ 
3N. Ammonia; 7:2:3, v/v)
Standards
Labelled fructose metabolites
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Fig. 19 continued
Paper electrophoresis (ammonium formate buffer; 0.1M, pH 3.8)
cpu
Standards
Ul'ilJLL'l ccco
Labelled fructose metabolites
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TABLE XIX* Fructose metabolism by liver extracts from male and
female rats
-4C.p.m. X 10 /I5 min./mg.sol.protein
Products
* 4 Male ^ * . /Female
-d
Male ^
** d 
Female
Fructose 1- 
phosphate 240.0
(48%) 190.0 (38%) 51.0 (18.6%) 49.0 (18.0%)
Dihydroxy-
acetone
phosphate
15.2
(3.0%) 5.8 (1.2%) 1.65 (0.6%) 1.51 (0.55%)
a-glycero-
phosphate
12.3
(2.5%) 5.0 (1.0%) 1.87 (0.7%) 1.25 (0.45%)
p-glycero-
phosphate
(?)
2.47 (0.9%) 1.31 (0.43%)
Fructose 1,6 
diphosphate 8.0
(1.6%)
11.9 (2.0%) 1.30 (0.47%) 1.62 (0.59%)
Fructose 180.0
(36%)
230.0 (46%) 191.0 (70%) 192.3 (70%)
♦ 12-13 wk. old animals; initial fructose concentration 0.1M,
5*0 % 10 ^ c.p.m.
** 14-15 wk* old animals; initial fructose concentration 0.2M,
2.8 % 10 * c.p.m.
/ Liver preparation was obtained from a single animal.
Numbers in parenthesis represent % incorporation of label.
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Fructose
F - .6 - P.
yv
Glyceraldehyde-3-P DHAP Glyceraldehyde
Glycerol
o-glycerophosphate
Triglyceride.
Fig. 20. The triose interconversions in fructose metabolism
This could result in increased conversion of dihydroxyacetone phosphate
and glyceraldehyde to fructose 1,6-diphosphate (see Fig. 2). These
ideas do not, of course, take into account possible differences in pool
sizes between males and females.
Vihen liver preparations from older (14-15% week) animals were 
14
incubated with C-fructose and ATP using a higher initial concentration 
(0.2M) of ketose the male/female differences were hardly significant 
and in comparison with preparations from younger animals fructose 
utilization and fructose 1-phosphate formation were decreased. It is 
not known whether these results are due to inhibition caused by the 
use of higher concentrations of fructose or whether with the older 
animals the differences in metabolism between the sexes is less apparent. 
In this connection we have already discussed (p.70) our observation that 
the difference in rates of fructose phosphorylation between the sexes 
became less with increasing age of the animals.
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In further work, some of the products of fructose metabolism 
by livers from rats of different ages and sex were studied using 
animals from the same litters. The results shown in Fig. 21-23 are 
difficult to interpret and again possible differences in pool sizes 
have not been taken into account. However, with young week) 
animals of both sexes there appears to be no significant difference 
in the amount of label appearing in the dihydroxyacetone phosphate 
(Fig. 21), This may mean that rates of formation and utilization of 
dihydroxyacetone phosphate are the same for both sexes or that these 
rates are different but so balanced as to produce the same amount of 
labelling in each case. With adult animals there is a differential 
and liver extracts from males appear to be more efficient in incor­
porating label than are those from females (cf. Table XIX). 
Conversion of fructose to o-glycerophosphate (Fig. 22) may proceed 
at a similar rate in young male and female rat livers. With adult 
animals however, the male tissue extracts incorporate 16 times as 
much label into a-glycerophosphate as do the female extracts (cf. 
Table XIX). It is possible from these results that triose formation 
from fructose is favoured in the case of male livers. This could be 
explained on the basis of higher levels of fructokinase, fructose 1- 
phosphate aldolase and glycerokinase in male as compared with female 
tissues, but it is possible that other enzymes in the fructose 
metabolic pathway shown in Fig. 2 do play an important role. The 
formation of fructose 1,6-diphosphate from fructose has already been 
referred to on P.97. The results shown in Table XIX and Fig.23 for 
the production of the diphosphate are similar, ^  that slightly more 
is produced by female than by male liver tissue extracts from 11-13 
week animals. Livers from 3^ week animals of both sexes incorporate 
significantly more label from fructose into fructose 1,6-diphosphate 
than do tissues from older rats.
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Conclusion
The original intention was to discover sex differences in the 
metabolism of fructose in rats, which could possibly be related to 
those in man, and hence to sex differences in serum triglycerides and 
the incidence of heart disease.
It is apparent from the present study that there are important 
differences in fructose metabolism in male and female animals.
The activities of fructokinase, fructose 1-phosphate aldolase 
and glycerokinase (see P.97) are considerably greater in male than in 
female liver tissues of adult rats. Testosterone was observed to 
elevate fructokinase activity in both male and female animals whereas 
estrone decreased enzyme activity in the males but increasedit in 
females. It is fairly certain, therefore, that fructokinase activity 
in normal animals is under control of sex hormones as are probably 
the aldolase and glycerokinase. Castration and/or adrenalectomy of 
animals would provide further information regarding this theory as 
would experiments on liver enzymes obtained at different times in the 
estrous cycle. In the absence of further evidence control at the 
level of protein synthesis presumably occurs.
The higher levels of labelled dihydroxyacetone phosphate and
a-glycerophosphate present in male rat liver tissues (after Incubation 
14with C-fructose) compared with female tissues may also indicate sex 
differences in the pathway to triglycerides. It is obvious that 
future work should include an investigation of hormonal control of 
reactions leading from triose to fats.
In view of the differences in fructose metabolism and serum 
triglycerides in men and women and the closely allied effects of 
androgens and estrogens on fructose metabolism in rats, it is logical 
to suppose that sex hormones play related roles in both organisms.
This, of course, must be confirmed by the appropriate experiments on 
enzyme levels in human liver tissues and the effect of exogenous sex 
hormones on these activities. The effect of changing hormone levels 
associated with the menstrual cycle and the onset of the menopause 
could also be investigated if suitable biopsy samples could be obtained.
In conclusion, there is every reason to suppose that the conversion
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of fructose (and sucrose) to triglycerides is Influenced by the 
products of the sex organs. The relationship between high serum 
lipid levels and coronary thrombosis is at present, however, 
mainly based on statistics. It is to be hoped that further 
biochemical investigations will show if there is a direct linkage 
between fructose and coronary thrombosis via serum lipids. With 
regard to preventive therapy, confirmation of such a linkage 
would be welcomed as the incidence of the disease might then be 
drastically reduced by careful control of sucrose in the diet.
E X P E R I M E N T A L
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Materials; Analar grade chemicals were used whenever possible; other 
chemicals were of the best available purity.
Glass distilled, deionised water was used for preparation of 
solutions.
Animals; Male and female Wistar-strain rats from 3 days of age to 17 
weeks were used for in vivo studies. In vitro studies were conducted 
with animals aged 8-11 weeks. The animals were fed on a commercial 
stock diet ad lib, and killed as needed by cervical fracture.
General Methods
1) Paper chromatography; Whatman No. 1 and No. 3 papers were used 
throughout and these were developed by the descending elution
technique. The chromatograms were developed for 1-43 hr.
Solvents
(i) ethyl acetate/acetic acid/formic acid/water (18:3:1:4; v/v,
(345)).
(ii) methoxycthanol/methyl ethyl ketone/3N ammonia (7:2:3; v/v ,
(346)).
Locating reagents
(a) Carbohydrates were located using a silver nitrate solution 
in acetone, followed by ethanolic sodium hydroxide (0.5 - 
2.0%) (347).
(b) Phosphates were detected by the formation of phosphomolybdate 
complexes which were subsequently reduced by irradiation with 
u.v. light (348)
2) Paper electrophoresis; Wliatman No. 1 paper was used for the high 
voltage (4000V, 80mA) paper electrophoresis. The papers were 
developed for % - 1^ hr.
Solvent
Ammonium formate buffer (pH 3.8) (349).
Locating reagents
The same reagents were used for detecting carbohydrates and 
phosphates as were described in the section on paper chromatography.
3) Radioactivity measurements: All radioactivity was measured on 
paper and counted to a 3% error with a Beckman LS100 scintillation
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counter, using a toluene scintillant (5g PPO : 0.3g POPOP : 1 .L 
toluene). The recovered radioactivity was 90-98% in all cases. 
Activity on paper chromatograms and electrophoretograms was 
located by the use of a Pye-Unicam 4 tt Scanner prior to deter­
mination in the scintillation counter.
4) Protein estimation; The protein content of all enzyme prepara­
tions was measured spectrophotometrically by the method of 
Lowry et al (350) except that the Folin-Ciocalteu reagent was 
diluted with an equal quantity of water. Human serum albumin 
was used as a standard.
5) Spectroscopy; Absorbance of coloured solutions was measured 
using a Unicam S.P.500 spectrophotometer.
Ill
EXPERIMENTAL
1) Incorporation of ^^C-fructose and ^^O-glucose into liver 
triglycerides.
Liver slices from male and female rats were incubated in Krebs-
14Ringer bicarbonate solutions (10ml.) (351) containing C-(U)-
14
fructose (0.023 pmoles; 2.89mCi/mMole and C-(U)-glucose (0.18 x 
10*^pmolesj ?89mCi/mMole), respectively. Incubation time varied 
from 1-2hr. after which the slices were washed twice with ice-cold 
Krebs-Ringer solution. The washings were added to the original 
incubation medium which was evaporated to dryness and redissolved 
in a known volume of water (I9I) to determine the residual radio­
activity. The procedure for the extraction of lipids as described 
in Appendix 2, was carried out. After saponification and acid 
treatment the aqueous solution containing glycerol was evaporated 
to dryness. The glycerol was extracted twice with ethzmol, reduced 
to dryness both times and finally taken up in a known volume of 
ethanol.
Similarly,the petroleum layer containing the fatty acids was 
evaporated to dryness and the fatty acids finally dissolved in a 
known volume of petroleum ether. The radioactivities of the glycerol 
and triglyceride fatty acid fractions were measured.
2) Preparation of soluble liver protein fractions
(a) Livers were homogenized in 50 mM-sodium cacodylate buffer 
(1:3 (w/v); pH 6.5) using a Potter-Elvehjem homogenizer with a 
bore volume of 60ml. and 0.48mm. clearance. The homogenates 
were either filtered through 4 layers of muslin or centrifuged 
at 5000g for 10 min. to remove ruptured membrane protein before 
centrifugation at 100,000g for 1 hr. The resulting supernatant 
solutions were used to perform all fructokinase assays.
(b) In the case of fructose 1-phosphate aldolase studies, livers 
were homogenized in 75mM-glycyl';-glycine buffer (Is3 (w/v);
pH 7.5), and the procedure described above repeated.
3) Fructokinase assay
Two methods for determining fructokinase activity were used:
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(a) In several of the assays in which the effect of testosterone 
and estrone on male and female rat liver slices was investigated, 
fructokinase activity was determined on the basis of fructose 
disappearance as described by Hers (257,258). Fructose in this 
case was estimated by the colourimetric method developed by
Roe et al (352) and later modified by Hers (353). Enzyme solution 
(0.5ml.) was added to a well shaken, preheated (37* for 20 min.) 
mixture of 40mM-fructose (0.3ml.), 50n^-adenosine triphosphate 
(0.3ml.), f 50m^magnesium acetate , 4.0^potassium acetate
(0.9ml.) to which 0.5M-sodium fluoride (0.3ml.) had been added 
prior to the addition of the enzyme. The 37* temperature at 
pH 6.5 was maintained for 15 min. and then deproteinization was 
effected by the successive addition of zinc sulphate and barium 
hydroxide solutions.
(b) hhen measuring fructokinase activity in:-
(i) the livers of male and female rats injected with 
testosterone and estrone;
(ii) the livers of rats over a range of ages;
(iii) enzyme preparations incubated with large concentrations
14of C-fructose;
(iv) liver slices incubated with testosterone, and
(v) liver slices incubated with testosterone and
cycloheximide,
a modified version of the procedure described in (a) was used.
The reaction mixtures were incubated in capillary tubes at 37*.
The composition of the digests was as follows;
14
40m^ C-fructose (2.89mCi/mMole) (5pl); 50 mM-adenosine triphosphate 
(5pl), (50mM-magnesium acetate (5pl)>, 4.0M-potassium acetate (13pl), 
0.5M-sodium fluoride (5pl) and enzyme extract (5-20pi).
After incubation the reaction was stopped by placing the tubes in 
an acetone-dry ice mixture. Each tube was individually thawed and 
the contents quickly spotted on chromatography paper which was then 
developed as described in General Methods (1). The chromatograms 
were scanned for radioactivity using a Pye-Unicam 4rr scanner and 
the areas of paper containing the labelled products (identified by 
the use of standards) were then cut from the chromatograms and the.: 
radioactivity measured as described in General Methods (3).
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Enzyme activity was expressed in terms of pmoXes fructose 
utilized/mg. soluble protein or/g.wet wt. liver at 37*.
144) Preparation of C-fructose 1-phosphate 
14C-Fructose 1-phosphate was prepared using the soluble liver 
protein fraction (described in Experimental (2)) as source of 
fructokinase. 15.2mî^^^C-fructose (6.08pmoles; 65.8mCi/mMole) 
plus 38#5n^ fructose (15.4pmoles) was incubated with) {enzyme 
(160pi), 50mM-adenosine triphosphate (40pl), 50mM magnesium acetate 
(40pl), 4.0M-potassium acetate (120pl) and 0.5M sodium fluoride f40pl) for 
15 min. at pH 6.5 and the resulting fructose 1-phosphate isolated 
by preparative paper chromatography. The conversion was 90% and a 
total of 4,56pmoles of ^^C-fructose 1-phosphate (65.8mCi/mMole) and 
ll.Spmoles fructose 1-phosphate was obtained.
5) Fructose 1-phosphate aldolase assay
Fructose 1-phosphate aldolase was assayed by the addition of
the enzyme preparation (20pl) (prepared as described in Experimental 
14
(2b)) to l0.9mM C-fructose 1-phosphate (5pl) and 0.5M sodium
fluoride (5pl) (cf 354). Incubations were carried out in capillary
tubes at 37*. Reactions were stopped by immersion in acetone-dry ice
mixtures and the contents of the tubes were subsequently spotted on
paper chromatograms which were treated as described in General
Methods (1). The residual fructose 1-phosphate and products were
detected with a Pye Unicam 4 7T Scanner and accurate measurements of 
14C-content then made by scintillation counting of the appropriate 
strips removed from the chromatograms.
The enzyme activity was expressed as c.p.m. products/mg. sol. 
protein at 37*.
6) Subcellular fractionation of rat livers
The method employed was essentially that of Schneider and 
Hogeboom (337). The livers (7.0-10.5g) were removed and washed with 
ice-cold 0.25^sucrose-50mJ^sodiuffl cacodylate solution (pH 6.5), 
blotted on filter paper, and then cut into pieces and homogenised in 
5 vol. (w/v) of fresh Ice-cold 0.25^sucrose-50mM-sodium cacodylate
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solution by ten passes in a Potter-Elvehjem homogenizer. The 
homogenatc was filtered through 4 layers of muslin and then 
fractionated with a M.S.E. Superspeed 50 centrifuge by differential 
centrifugation at 0-4* as follows:
HOMOGENATE
centrifuged for 10 min. 
at 650g.
NUCLEAR
FRACTION
i
SUPERNATANT
centrifuged for 10 min. 
at 22,500g.
SUPERNATANT
;
MICRÔSOMES
centrifuged for 
30 min. at
100,000g.
J
SOLUBLE
SUPERNATANT
LYSOSOMES AND 
MITOCHONDRIA
Each sediment was re-suspended in the same sucrose-buffer medium 
(5ml) and recentrifuged at the appropriate speed. This resuspension 
was repeated and the washings were added to the corresponding super­
natant solutions. All the fractions were frozen and thawed 3 times 
using acetone and dry ice, and the ruptured membranes then removed by 
centrifugation at 100,000g for 1 hr.
Fructokinase assays were performed on all the soluble supernatant 
solutions.
(cf K. Clarke, Ph.D. Thesis,
7) Zonal centrifugation technique University of London, 1971)
Subcellular fractions of rat liver were obtained by the method
described in Experimental (6). Zonal centrifugation using a M.S.E.
Superspeed 65 centrifuge fitted with a B-XIV titanium zonal rotor was
used to separate the Lysosomal & Mitochondrial fractions. Fig. 25
shows all the connected fluid lines which were kept as short as possible,
(i) Loading the rotor: 17% (w/w, 1.0719g cm ^) sucrose (325ml)
and 55% (w/w, 1.2663g Cra*^ ) sucrose (275ml) solutions (355) were
placed in their respective compartments of the gradient former.
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Fig. 25.Schematic diagram showing fluid line connections with the B-XIV titanium zonal rotor. STIRRER
BUBBLE
TRAP
55'ro se
GRADIENT FORMER
COOLING PERISTALTIC GRADIENT 
PUMP
FEED HEAD ASSB-BLY
I I 
I I
-XIV ZONAL ROTOR
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which was kept at 0°C by surrounding it with ice* With fluid 
lines A and D clamped, 17% sucrose solution was pumped through 
the vertical line C in order to check that there were no air 
bubbles in the system. Line C was clamped and lines A,B,D and 
B opened. The stirrer was set in motion to ensure thorough 
mixing of the light and heavy sucrose solutions and a linear 
with volume sucrose-density gradient was pumped into the zonal 
Kotor at a flow rate of 15ml./min. whilst the rotor was rotating 
at 2,500 r.p.ra. This was immediately followed by 60% (w/w,
1,2955g cm*^) sucrose solution (50ml.j the 'cushion* fluid), 
pre-coolcd to 0®, which resulted in the 17% sucrose emerging 
through line B and indicated that the rotor was full. The 
temperature for all subsequent operations was kept at 0-4^.
Lines £ and B were then clamped and 0.25M sucrose-50mM sodium 
cacodylate (10ml.; 1.0349g cm“ ,^ pH 6.5, 0®) containing the 
sample was applied with a 20ml. syringe at a flow rate of 2.5ml./ 
min. to the rotor through line £, with line C open. The flow 
rate was found by measuring the exudate from line C. Air was 
not allowed to enter line C, so that the gradient would not be 
disturbed by air bubbles. Line £ was clamped and the 20ml. 
syringe replaced by a 50ml. syringe, containing light mineral 
oil; with £ open, the light oil was pumped into the rotor at a 
flow rate of 2.5ml./min. and this ensured the sample zone was 
moved from the core of the rotor into a region of higher gravi­
tational field. On completion, lines B,C,0 and £ were clamped, 
the rotor feed head assembly removed and the rotor capped.
After centrifuging the rotor was decelerated to 2,500 r.p.m. 
before unloading.
(ii) Unloading the retort
The feed assembly was replaced and the fluid lines B,D and 
£ opened. Sucrose solution (60% w/w) was pumped into the rotor, v 
through line D, at a flow rate of 15ml./min. The gradient 
containing the separated sample material was displaced through 
the rotor core and line £ and fractions collected (5ml.) which 
were kept surrounded by ice.
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The lysosomal fractions and the mitochondrial fractions were 
separately pooled, diluted to 250ml. with buffer, and centrifuged at 
12,000 r.p.m. for 1 hour. The subcellular particles were resuspended 
in 50r^-sodium cacodylate buffer (5 ml.), frozen and thawed three 
times using acetone and dry ice and the ruptured membranes then 
removed by centrifugation at 100,000g for 1 hr. The supernatant 
solutions were assayed for fructokinase activity.
8) Relative fructokinase and hexokinase activity in liver tissue
preparations.
One male rat (244g) and one female rat (218g) were killed and 
the livers immediately excised, dried and weighed, and each liver 
independently homogenized. The soluble protein preparations were 
prepared as described in Experimental 2(a) and both enzyme preparations 
were divided into two fractions. A fructokinase assay (assay (b)) was 
performed on one fraction; the second fraction was acidified to pH 6.0, 
centrifuged at 20,000g for 20 min. and readjusted to pH 6.5. Fructo­
kinase activity was then determined using assay (b) after the addition 
of 0.5M 2-acetamido 2-deoxy-p-glucose (5pl) (259).
9) Hormone injection studies
Male and female rats weighing between 150-280g were injected 
subcutaneously with the following hormones In a saline/propylene glycol 
mixture (1ml.) (see E3q>erimental (10))%
(i) testosterone (3, 12 and 24mg./Kg. body wt,);
(ii) estrone (24mg./Kg. body wt.).
Control animals were injected with saline/propylene glycol 
(1ml.). 6 rats were used with each hormone.
The animals were killed at various times (1-72hr.) after 
injection; the livers were immediately excised and soluble protein 
fractions prepared independently from each liver as described in 
Experimental (2).
Fructokinase and fructose 1-phosphate aldolase activities were 
determined.
10) Preparation of steroid suspensions
The steroid hormones are relatively insoluble in aqueous media, 
hence, all treatments were made with a fine suspension of hormones.
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Testosterone and estrone were first dissolved in propylene glycol 
at 50^ before the addition of saline solution (0.9%)or Krebs-Ringer 
bicarbonate solution. In this procedure the final organic phase 
in the medium did not exceed 0.5% (356).
11) Studies with liver slices
Liver slices were prepared as described by Deutsch (357).
The slices (200-300mg. wet wt.) were placed in stoppered glass tubes 
containing Krebs-Ringer bicarbonate solution (10ml) with and without 
added steroid hormone. Control media also contained propylene 
glycol. The tubes were incubated in a water bath at 37^ with shaking.
After incubation, the slices were removed from the medium, 
washed thoroughly in ice-cold Krebs-Ringer bicarbonate solution and 
dried on filter-paper. The slices from each tube were homogenized 
in 50m^sodium cacodylate buffer (pH 6.5; ( 3ml), in a Potter-Elvehjem 
homogenizer (vol. 7ml, fitted with a teflon pestle with a clearance 
of 0.23mm.) and centrifuged at 100,000g for 1 hr. (0-4°). Enzyme 
assays were carried out on the supernatant fraction.
12) Effect of cycloheximide on fructokinase activity in rat liver 
slices.
Liver slices were incubated in Krebs-Ringer bicarbonate solution 
(as described in Esq^crimental (ID) with testosterone (Img./IOml.sol.) 
and testosterone (Img./IOml.sol.) plus cycloheximide (final concen­
tration in medium 4mM) (358). Control media contained propylene 
glycol. Soluble protein preparations were made and enzyme assays 
carried out as described in Experimental (11).
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Appendix 1
Partial purification of Fructokinase
A purification of fructokinase was carried out with the 
intention of studying possible direct in vitro effects of sex 
hormones on the enzyme.
A 20-fold purification of fructokinase from male rat liver 
was obtained by a modification of the method of Hers (257).
The rat was killed by cervical fracture, the liver excised 
and macerated in a M.S.E. Homogenizer (3 min. max. r.p.m.) with 
ice-cold 50mM sodium cacodylate buffer (1:3, w/v; pH 6.5). The 
homogenate maintained at 0° was acidified to pH 4.5 with N-HCl and 
then immediately adjusted to pH 5.5 with 0.5N KaOH. The denatured 
protein was centrifuged off (9000g, 30 min.) and the clear super­
natant adjusted to pH 7.5 and fractionated with ammonium sulphate.
The precipitate appearing at 0.4-0.6 saturation was centrifuged 
off (9,000g, 20 min.) and dissolved in 50n]M sodium cacodylate buffer
and then dialyzed against cacodylate buffer Ï2L) for 24 hr. at 4°.
14The enzyme activity was assayed using C-fructose (see P.112) 
and the results ejqiressed as fructose 1-phosphate c.p.m. x 10^^/ 
min./mg.sol. protein.
Activity
Crude enzyme 3.0
0.4-0.6 ammonium 
sulphate fraction 66.0
The purified enzyme was used to investigate the action of sex 
hormones in vitro, however, severe difficulties were esq^erienced with 
hormone solubilities and the results obtained were considered to be 
dubious, and hence are not reported in this thesis.
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Appendix 2
Gas-liquid chromatographic separation of fatty acids
In an early stage of this investigation attempts were made
14to examine the incorporation of label from C-fructose into 
individual glyceride fatty acids. This study was later abandoned, 
however, in view of the difficulty of interpreting the very complex 
series of reactions involved. However, a preliminary examination 
of the glyceride fatty acid composition of a number of rat tissues 
was made and this is reported here.
Rat tissues (liver, heart, arterial) and serum were added to 
Bloor’s solvent (ethanolidiethyl ether; 3x1 v/v) (344) and the 
mixtures brought to the boil and filtered. The protein precipitates 
were washed twice with Bloor*s solvent and the combined extracts 
evaporated to dryness. The residues after three extractions with 
hot petroleum ether (B.P.40-60°), and filtration,were then reduced in 
volume and applied to Silica gel thin layer chromatography plates.
These were developed with a petroleum ether (40-60°)t diethyl ether s 
glacial acetic acid (82x18:1; v/v) solvent, then dried and stained 
with iodine vapour to identify the glyceride fraction. The iodine 
was allowed to sublime off and the glycerides scraped off the plate, 
dissolved in petroleum ether, centrifuged and finally saponified with 
ethanolic KOH (11% w/v). The mixtures were acidified with N-HCl and 
the two layers allowed to separate. The petroleum layers containing 
the fatty acids were isolated and reduced in volume,then placed in 
flasks and treated with excess boron trifluoride-methanol complex 
(14% BP^ in methanol). The flasks were gassed with nitrogen, sealed 
and incubated at 60° for 30 min. The BF^-methanol mixtures were 
removed by washing with water and the organic layers then separated, 
dried with anhydrous sodium sulphate and evaporated to dryness. The 
methylated acids were taken up in a known volume of petroleum ether 
(B.P.40-60°) and analysed immediately by gas-liquid chromatography 
using a Perkin Elmer F11 Gas Chromatograph fitted with a hydrogen 
flame ionization detector with nitrogen as a carrier gas. The temperatiire 
used was in the range 175-190° and the column (6ft x ^  in.) contained
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20% Diethyl glycol succinate (DECS) on a HMDS Chromosorb inf. 80-100 
mesh support.
The major bound fatty acids in the rat liver (see Fig. 24) 
were found to be myristic, palmitic, stearic, oleic and linoleic. 
There appeared to be qualitative differences between various tissues 
and it is particularly interesting to note differences between 
different lobes of the liver. This latter observation should be 
borne in mind when examining the metabolism of liver cells.
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